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CHAPTER 1
INTRODUCTION
GPI TRANSAMIDASE AND GPI ANCHORED PROTEINS: ONCOGENES AND
BIOMARKERS FOR CANCER
Most of this chapter was published in an invited review: Gamage, D. G. and
Hendrickson, T. L. “GPI transamidase and GPI anchored proteins: oncogenes
and biomarkers for cancer.” 2013, Crit. Rev. Biochem. Mol Biol. 48(5): 446-464

1.1 Introduction
Cancer is caused by uncontrolled abnormal cell growth. According to
statistics from the American Cancer Society, in the United States nearly one in
two men and one in three women will develop a cancer in his or her lifetime.
Cancer is also a public health threat worldwide. Geographic variations in cancer
types and prevalence can arise from differences in regional lifestyle, genetics,
diet and pollution, amongst other factors.1
In addition to the emotional toll of cancer on patients, family, and friends,
statistics from the American Cancer Society illustrate the devastating economic
impact of cancer worldwide, which stem from direct costs for medical care and
rehabilitation and indirect costs from morbidity and mortality.1 In order to reduce
cancer mortality and improve each patient’s quality of life, it is important to
understand how different oncogenes and biomarkers participate in cancer onset,
progression, and metastasis. Several well established cancer biomarkers,
including the urokinase plasminogen-activated receptor (uPAR) and the folate
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receptor, are C-terminally modified with a glycosylphosphatidylinositol (GPI)
anchor.2,3 This glycolipid anchor is clearly essential for proper translocation of
these proteins; however, evidence supporting any further functional involvement
for the GPI anchor, particularly with respect to tumor phenotypes, was minimal.
In 2004, the discovery of the GPI anchor biosynthesis class U protein (PIG-U) as
an oncogene in human bladder cancer opened a new door to the possibility that
the enzyme involved in GPI anchoring, called GPI transamidase or GPI-T, might
itself be tumorigenic.4 PIG-U is one of the five subunits that comprise the human
GPI-T although the function of PIG-U in this enzyme is unknown.5 The reaction
catalyzed by GPI-T and the chemical structure of a typical human GPI anchor are
shown in Figure 1.1.
GPI membrane anchoring of proteins is an abundant phenomenon that
specifically tethers proteins to lipid bilayers. Approximately 0.5% of all eukaryotic
proteins are modified or predicted to be modified by GPI-T to contain a GPI
anchor.6 GPI anchored proteins are almost exclusively localized on the cell
surface where they are non-covalently associated with the plasma membrane via
the lipid portion of the anchor. GPI anchored proteins are engaged in diverse
processes like immune recognition, cellular communication, signal transduction,
and embryogenesis.7,8,9,10,11 Loss of GPI anchoring is embryonically lethal to
mammals and conditionally lethal to yeast.10,

12,13

Defects in GPI anchor

biosynthesis can cause diseases like paroxysmal nocturnal hemoglobinuria and
hyperphosphatasia mental retardation syndrome and a mutation in the PIG-T
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Figure 1.1: The chemical structure of the GPI anchor and the reaction
catalyzed by GPI-T. (a) Left: The basic chemical structure of a human GPI
anchor from nucleated cells is shown as a representative example. Right: A
simplified cartoon representation of this GPI anchor. (b) The reaction catalyzed
by GPI-T. GPI-T displaces the C-terminal signal sequence in the proprotein
substrate with a GPI anchor, forming a new amide bond between the ω site
carbonyl and the amine from the phosphoethanolamine group on the third
mannose in the GPI anchor. Figure 1.5 shows the mechanism of this reaction in
greater detail.
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subunit of GPI-T is connected to an intellectual disorder.14,15,16 These different
diseases highlight the importance of GPI anchoring of proteins to normal cell
biology. This introductory chapter focuses specifically on the connections that link
GPI membrane anchoring to abnormal cell biology and cancer.
GPI-T is a complicated and poorly understood enzyme. GPI-T is a
membrane bound, multi-subunit protein complex found in the endoplasmic
reticulum (ER). This enzyme contains five known subunits, PIG-K, PIG-T,
GPAA1, PIG-S, PIG-U in humans5,12,17 (analogous to Gpi8, Gpi16, Gaa1, Gpi17
and Gab1 in yeast5,12,18,19). PIG-U, the last subunit of GPI-T was identified more
than a decade ago and yet clear functional assignments for all but one of these
subunits have remained elusive. The exception is PIG-K (Gpi8): this subunit
comprises the catalytic machinery of the enzyme.12,20 Understanding how
changes in gene overexpression participate in tumor onset or progression is
difficult without a clear picture of the enzyme itself in terms of its structure and
function.

1.2 The GPI anchor: A substrate for GPI-T
GPI anchors contain a common core structure that is conserved across
eukaryotes and contains an ethanolamine phosphate, three mannoses, a
glucosamine and a phosphatidylinositol group (Figure 1.1). However, tissue- and
species-specific core modifications and elaborations were identified in GPI
anchors from different sources.21,22,23,24,25 The complete biosynthetic pathway to
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produce the GPI anchor was fully revealed by the early 2000’s (Figure 1.2). This
pathway requires more than 20 gene products, making GPI anchoring of proteins
one of the most complex and metabolically expensive post-translational
modifications.9,26,27 The different enzymes involved in GPI biosynthesis have
been characterized to varying extents. Most are hydrophobic and reside in the
ER membrane (recently reviewed by Fujita and Kinoshita).9
GPI anchors are present in minute amounts in human and fungal cells and
are also challenging to synthesize and purify. Due to this complexity, small
nucleophiles like hydrazine, hydroxylamine, and biotin hydrazide were identified
as useful GPI anchor mimics.28 These GPI anchor surrogates were used early on
to characterize the reaction catalyzed by GPI-T.
Because of limitations faced when isolating GPI anchors from their natural
environments, it has remained challenging to understand the contributions made
by different monosaccharides or modifications. Syntheses of short series of GPI
anchor analogues have been reported.29,30 Synthesis of the full-length CD52
peptide, with its N-linked glycan and most of its GPI anchor, was reported about
10 years ago and was recently followed up by the synthesis of a complete GPI
anchor (from the human lymphocyte CD52 antigen).31,32 These synthetic
compounds (full-length anchors, synthetic GPI anchored proteins, anchor mimics
and anchor analogues) can be used not only to better understand GPI-T but also
to investigate the functions of GPI anchored proteins in cells and for vaccine
development. In fact, synthetic GPI glycans were used in microarray studies to
examine antitoxic malaria responses and to develop carbohydrate-based
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(6)
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Phosphate

N-acetyl glucosamine

Inositol
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Figure 1.2: Biosynthetic pathway for GPI anchors in human nucleated cells.
The GPI anchor is synthesized in the ER starting from phosphoinositol. At least
ten enzymes are needed for this pathway; these enzymes are summarized in the
table 1.1. The first two steps of the synthesis take place on the cytoplasmic side
of the ER and steps 4 through 10 occur on the luminal side. Later steps in this
pathway can vary in different types of cells.
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vaccines to treat severe malaria.33,34 Another recent study used an azide-labeled
N-acetylgalactosamine analog (GalNAz) to understand the immobilization of GPI
anchored proteins inside the cell as well as to analyze the functional roles of
branch modifications.35
Defects in different GPI anchor biosynthetic steps cause several types of
inheritable and acquired diseases. For a recent review see Almeida et.al..36 To
our knowledge, defects in GPI anchor biosynthesis have not been directly linked
to cancer onset or propagation. However, patients with paroxysmal nocturnal
hemoglobinuria (PNH), a hemolytic disorder that results from a somatic mutation
in PIGA (See Table 1.1), are at increased risk of developing acute leukemia.14

1.3 Protein substrates for GPI-T
Proteins designated to be GPI anchored are ribosomally synthesized as
preproproteins and contain an N-terminal signal sequences targeting them for
translocation into the ER. Historically, it has been assumed that substrates for
GPI-T enter the ER via the secretory recognition particle (SRP).37 However, a
recent report made the compelling argument that these preproproteins are
predominantly delivered to the ER by an SRP-independent pathway.38 This
process relies on recognition of both the N-terminal signal peptide and the Cterminal

GPI-T-specific

signal

sequence

(described

below).

Once

the

preproprotein is delivered to the ER, the N-terminal signal sequence is cleaved
by signal peptidase. The resultant proprotein is recognized by GPI-T and the C-

	
  
	
  

8	
  
	
  

Table 1.1: Enzymes involved in GPI anchor biosynthesis in human
nucleated cells. Additional modification reactions are known to occur in other
types of cells.

Step

Enzyme complex

Proteins involved

1

GPI-GlcNActransferase39,40,41,42

PIG-A, PIG-C, PIG-H, PIG-P, PIGQ, PIG-Y, DPM2

2

GlcNAc-PI de-N-acetylase41

PIG-L

3

Flippase43

Unknown

4

Inositol acyltransferase44

PIG-W

5

α1-4 mannosyltransferase I45,46

PIG-M, PIG-X

6

α1-6 mannosyltransferase II47

PIG-V

7

EtNPtransferase I48

PIG-N

8

α1-2 mannosyltransferase III49

PIG-B

9

α1-2 mannosyltransferase IV50

PIG-Z

10

EtNPtransferase III51

PIG-O, PIG-F
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terminal GPI-T signal sequence is displaced upon conversion to the mature GPI
anchored protein (Figure 1.3 and Table 1.1). The use of an SRP-independent
pathway for translocation to the ER clearly defines GPI membrane anchoring as
a post-translational protein modification.
GPI-T recognizes and cleaves the C-terminal signal sequence of the
proprotein at the ω-site, forming a new amide bond between the ω-site carbonyl
and the appropriate amine on the GPI anchor. The ω-site is so named because it
becomes the C-terminal residue of the mature GPI anchored protein. This
residue is immediately followed by the ω+1 and ω+2 residues (and so forth
towards the C-terminus); the remainder of this C-terminal sequence is composed
of a hydrophilic spacer and a hydrophobic peptide.52,53 Several studies have
analyzed the identity of the ω-site amino acid and GPI-T’s ability to tolerate
substitutions. Most of this work relied on a protein construct called
preprominiPLAP,
phosphatase.

a

minimalistic

version

of

human

placental

alkaline

PreprominiPLAP promoted significant advances in the field

because it contained an engineered poly-Met sequence suitable for metabolic
labeling with 35S-Met and it was significantly smaller than native PLAP so that the
different processing intermediates could be resolved by gel electrophoresis
(namely, the preproprotein, the proprotein, and the GPI anchored protein, as well
as a truncated hydrolytic product).54,55 Analysis of preprominiPLAP mutants
revealed that alanine, cysteine, glycine, asparagine and serine are good ω-site
candidates for human GPI-T. Similar results were obtained using human decay
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(a) The PreProProtein

N-terminal
signal
sequence

ω

Soluble domain of the protein

ω +1 ω +2

Hydrophilic Hydrophobic
region
region

Small Amino
Acid Domain

(b) The ProProtein

ω

Soluble domain of the protein

ω +1 ω +2

Small Amino
Acid Domain

Hydrophilic Hydrophobic
region
region

(c) The GPI anchored Protein

ω

Soluble domain of the protein

Figure 1.3: Cartoon schematic of a protein substrate for GPI-T and its
processing intermediates. The preproprotein (a), which is destined for GPI
anchoring, has an N-terminal signal sequence that is cleaved by signal peptidase
to produce the proprotein (b). The GPI-T signal sequence on the C-terminus of
this protein contains a hydrophilic region followed by a hydrophobic region. The
signal sequence is cleaved by GPI-T between the ω and ω+1 amino acids to
attach the GPI anchor, producing the mature, GPI anchored protein (c). (Refer to
Figure 1.1 for the symbols used to designate the GPI anchor.)
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accelerating factor (hDAF), another GPI anchored protein; in this case, aspartate
was identified as a good ω-site but cysteine was not.56,57 In general, the ω-site
residue should be a small, hydrophilic amino acid.54 The first web server to
predict the presence and identity of ω sites in protein sequences was put forward
in 1999, with a false positive prediction rate of only 0.3%.58
The ω+1 position is typically small but can be any amino acid other than
proline. The requirements for ω+2 are much more stringent.59,54 This position is
almost always alanine, glycine or serine.59,54 Because the ω to ω+2 positions
tend to be small amino acids, this region has been referred to as the Small
Amino acid Domain (SAD).52,59
The ω+2 residue is followed by the remainder of the GPI-T signal
sequence. This peptide is typically between 18 and 32 amino acids long and
ends at the C-terminus of the protein. It can be broken down into two sections, an
8-12 amino acid spacer sequence that is predominantly hydrophilic, followed by a
15-20 amino acid hydrophobic sequence.37,52,53 Remarkably, the GPI-T Cterminal signal sequence does not contain a consensus motif. In fact, in one
report, completely artificial signal sequences (e.g. Ser3-Thr8-Leu14) were
appended onto the C-terminus of CD46 and were shown to be viable, enabling
GPI anchoring in vivo.60 Consequently, recognition of this sequence by GPI-T is
analogous to recognition of the N-terminal secretory signal sequence by signal
peptidase, more than it is to the methods used by other co- and post-translational
modification enzymes to select their substrates. Recent findings suggest that the
hydrophobicity of the hydrophobic region needs to be marginal compared to type
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II transmembrane anchors.61 Similarly, the hydrophilic spacer lacks a consensus
sequence, but the relative hydrophilicity and the length of the peptide play
important roles.53,60 Amino acids N-terminal to the ω-site are required for GPI
anchoring but without sequence or size specificity.37,53,62,63
The smallest known GPI anchored protein is the CD52 or Campath-1
antigen. In humans, the full-length CD52 gene encodes a 61 amino acid protein
that begins with an N-terminal signal peptide that is 24 amino acids in length.
CD52’s C-terminal GPI-T signal sequence begins with the ω-site at Ser36 and
proceeds to the C-terminus (Ser61). Thus, the proprotein is 37 amino acids long
and the fully mature, GPI anchored protein contains only 12 amino acids.64
Despite the simplicity of the rules that define the GPI-T signal sequence,
some studies have suggested that GPI-T shows species specificity for its protein
substrates.65,66,67 General and species-specific prediction algorithms have been
developed and have revolutionized the ability of researchers to predict not only
GPI anchoring but also the identity of the one or two most likely ω-sites.58,68,69,70
One recent GPI-T signal peptide prediction tool demonstrates high accuracy
using a position-specific scoring matrix (PSSM).71,72 One thing that these in silico
analyses suggest is the possibility that GPI-T recognizes and processes more
than one ω-site in a single peptide, leading to subtle heterogeneity during
maturation. (In other words, a protein substrate with two putative ω-sites might
be processed at both positions so that a mixture is produced where the anchor
can be attached at either ω-site.) To our knowledge, the experimental
identification of processing at more than one ω-site has not yet been observed or
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reported. However, very few efforts at genome-wide characterizations of
anchored proteins, particularly with ω-site validation, have been reported, so this
possibility cannot be rejected at the present time.

1.4 The GPI Transamidase Complex
Five GPI-T subunits have been identified so far, with homologues in
eukaryotes ranging from yeast to humans; all five subunits are essential for the
attachment of GPI anchors to proteins. As mentioned above, these subunits are
called PIG-K, PIG-T, GPAA1, PIG-S, PIG-U in humans,5,12,17,73 analogous to
Gpi8, Gpi16, Gaa1, Gpi17, Gab1 in yeast, respectively.5,12,17,18,19 In Trypanosoma
brucei, PIG-U and PIG-T are replaced by TTA1 and TTA2, two unrelated
subunits.74 Table 1.2 summarizes the sizes of these different subunits as well as
their predicted number of transmembrane domains and glycosylation sites for
orthologs from humans, yeast, and T. brucei. For the remainder of this
introductory chapter, we will use the names of the human GPI-T subunits unless
specifically talking about an experiment conducted with GPI-T from other
species.
Homologues of PIG-K, GPAA1, and PIG-T are conserved across
eukaryotes. In yeast, these core subunits can be purified together as a
complex.18 In contrast, in humans, all five subunits can be isolated together.5
Based on mutagenic analyses and its similarity to caspases, the PIG-K subunit
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Table 1.2: Features of GPI-T from humans, S. cerevisiae, and T. brucei.
Specific references are provided for publications where a given TM domain or
glycosylation site was predicted or experimentally examined. Asterisks (*)
indicate glycosylation sites or TM regions that were only predicted in the UniProt
database.

Subunit

Size (kD)

Putative glycosylation sites

Transmembrane
regions

Human
PIG-K75

45.3

-

One*

GPAA176

67.6

Two: N203, N517

Eight

PIG-S75

61.7

Two: N267*, N370*

Two*

PIG-T77

65.7

Three: N164, N291*, N327*

One*

PIG-U75

50.1

-

Nine*
S. cerevisiae

Gpi878

47.4

Three: N23a, N256*, N346*

Gaa179

69.2

Two: N87, N383*b

Gpi1775

60.8

Five: N100*, N170*, N228*,
N247*, N299*

Two*

Gpi1680

68.8

Two: N28a, N184*

One

Gab175

44.7

-

One*
Six

Eight *
T. brucei

TbGpi881

36.7

One: N25

No

TbGaa182

51.2

-

Six

TbGpi1682

75.8

-

One

TTA182

41.9

Two: N79, N259

Two

TTA282

45.6

-

Six
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In yeast, both Gpi8 and Gpi16 contain reasonable N-linked glycosylation sites
within or immediately adjacent to their N-terminal signal peptides. These sites are
listed here for completeness but they have not been characterized; they may not
be glycosylated or may have been cleaved from the protein during N-terminal
processing.
b
N383 is predicted as a glycosylation site using UniProt75 However, Hamburger
et al. reported results that argue that this site is not glycosylated.78-79 N383 lies
between the second and third transmembrane domains of Gaa1 and is
presumably inaccessible to the glycosylation machinery.

was identified as the catalytic active site and is the best characterized of the five
known subunits.20,83,84 Possible roles for some of the remaining subunits have
been proposed and are discussed individually below. The hydrophobicity of the
subunits, the complexity of the GPI-T enzyme, and poor expression levels of the
different subunits have contributed to the lack of progress in further
characterization of this enzyme. Another drawback has been the lack of a highthroughput assay for GPI-T. Nearly all methods to assay this enzyme’s activity
are both cumbersome and qualitative. Significant data is accumulating that
supports the hypothesis that the GPI-T complex contains more than one copy of
some or all of its subunits. In particular, native PAGE analysis of the pure,
heterotrimeric GPI-T complex from yeast revealed that this complex resolves into
two assemblies with molecular weights of ~430 and ~650 kD.18 Given the
molecular weights of the individual subunits, a complex of only ~240 kD is
predicted. All three of these yeast GPI-T subunits (Gpi8, Gaa1, and Gpi16)
contain probable glycosylation sites (See Table 1.2), but it seems unlikely that
glycans could account for an increase in MW of the ~400 kD needed to explain
the 650 kD complex. Thus, Conzelmann and colleagues proposed higher order
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oligomerization for GPI-T.18 The human GPI-T complex (from HeLA cells) has a
velocity sedimentation value of 17S, also consistent with a globular complex with
a mass of ~450 kD.85 In this work, Gaa1 was also observed to interact with αand β-tubulin; thus the possibility that tubulin is the source of the increase in the
molecular weight of GPI-T in humans cannot be ruled out. (Tubulin was not
apparent in the yeast GPI-T complex analyzed by native gel.) Additionally, PIGK, the active site subunit of GPI-T, has sequence and putative structural similarity
to caspases. The soluble domain of Gpi8 (the PIG-K ortholog from yeast) partly
assembles into a homodimer when heterologously expressed in Escherichia coli,
analogous to caspase dimerization.83 Gpi16 is attached to Gpi8 by a known
disulfide bond86 (see below); thus, by analogy, the hypothesis that the Gpi8
homodimer is symmetrically modified by two Gpi16 subunits is intuitive. Gpi8
dimerization has recently been called into question (discussed further in the next
section).12, 84 Understanding the stoichiometry and organization of GPI-T is going
to be crucial to understanding its function. Additional research is needed in this
area.
The next sections summarize what is known about the structures and
functions of the individual subunits of GPI-T. The possible functional roles for
each subunit, as they are currently understood, are discussed individually here
and are summarized for human GPI-T in Table 1.3. Their possible roles in cancer
will be discussed later in this introductory chapter.
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Table 1.3: Proposed functional roles for the five subunits of human GPI-T.

Subunit

Possible Roles or Functions
Similarities to caspases and other cysteine proteases

20,78,87

PIG-K

Contains all or some of the enzyme’s catalytic machinery
Attached to PIG-T by a disulfide bond

GPAA176

May contain part of the active site and be involved in peptide
binding and/or recognition

PIG-S88,89

Essential for thioester intermediate formation between PIG-K and
the protein substrate

87,88

PIG-T

Essential for carbonyl intermediate formation between PIG-K and
the protein substrate
Attached to PIG-K by a disulfide bond
Loosely associated with the rest of the GPI-T complex

PIG-U5,90

Weak similarity to fatty acid elongases
Possibly involved in lipid recognition or binding
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1.4.1 The PIG-K (Gpi8) subunit
PIG-K is the catalytic subunit of GPI-T. This ~47 kD subunit nominally
belongs to the C13 cysteine protease family.12,20 PIG-K has a large soluble
domain, oriented to the luminal side of the ER, and a single C-terminal
transmembrane region (Figure 1.4 (a)).12 The soluble domain has sequence
similarity to caspases, a family of cysteine proteases that regulate cell death.20
Analysis of conserved His and Cys residues indicated that His164 and Cys206
are the catalytic residues in human PIG-K (His157 and Cys199 in yeast).20,91 By
analogy to cysteine proteases, the histidine presumably deprotonates the
cysteine, which nucleophilically attacks the amide bond between the ω and ω+1
residues, creating a thioester intermediate, which is subsequently converted to a
new amide with the GPI anchor (Figure 1.5).92
A Rosetta-predicted structure of the soluble domain of yeast Gpi8 was
built based on putative structural homology between caspases and Gpi8 (Figure
4 (b)).83 This model positions the backbones of the two catalytic residues of GPIT (His157 and Cys199) in similar locations and orientations as their counterparts
in caspases. Caspases are active as homodimers, leading to the hypothesis that
Gpi8 also assembles into a homodimer, an oligomerization step that may be
essential for enzyme activity. Dimerization of the soluble domain of Gpi8 was
observed by native PAGE and by mass spectrometry. Furthermore, dimerization
was disrupted by the introduction of mutations at positions corresponding to the
face of caspase dimerization. Significant Gpi8 monomer was also observed in
this work, leading to the proposal that the Gpi8 dimer reflects the native
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Figure 1.4: The PIG-K subunit. (a) PIG-K has a single soluble domain (~340
amino acids) and one transmembrane domain. Human PIG-K is not glycosylated
however there are three sites of N-glycosylation in yeast Gpi8. The catalytic
cysteine (Cys206 in humans) is noted. PIG-K is connected to PIG-T via a single
disulfide bond (not shown). (b) The soluble domain of PIG-K has putative
sequence and structural homology with caspases.83, 93 The structure of caspase1 from Spodoptera frugiperda(PDB: 1M72, green) is overlayed onto a Rosetta
model of S. cerevisiae Gpi8 (magenta).83 (c) The sequences for portions of the
active site of human PIG-K (NP_005473), S. cerevisiae Gpi8 (NP_010618),
human caspase-14 (NP_036246), and S. frugiperda caspase-1 (AAC47442)
were aligned using Clustal W. Conserved residues are colored in blue, including
the histidine and cysteine that form the catalytic dyad for each enzyme. Residues
highlighted in magenta indicate positions that show similarity in at least three of
the four sequences. (d) A close up of the catalytic dyads in S. frugiperda
caspase-1 (green) and the model of S. cerevisiae Gpi8 (magenta) from panel B.
The active site cysteine in caspase-1 is shown alkylated by an irreversible
inhibitor. The model of Gpi8 places the His/Cys catalytic dyad within hydrogen
bonding distance.
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oligomerization state and that the monomer represents poorly folded or misfolded
Gpi8 as a consequence of heterologous expression in E. coli. Toh et al. recently
reported a very similar isolation of the soluble domain of Gpi8.84 However, they
used size exclusion chromatography (SEC) to isolate only the monomeric form of
Gpi8. It is unclear whether or not they examined their preparations for dimer and
it is probable that the Gpi8 dimer was lost during SEC purification. As discussed
above, clear evidence from two other research groups also support the
hypothesis that GPI-T assembles into a higher order oligomer in yeast and in
humans.18,85 Consequently, the preponderance of available evidence argue that
GPI-T

assembles

into

a

higher

order

oligomer.

However,

additional

characterization of this enzyme’s stoichiometry is clearly mandated.

1.4.2 The GPAA1 (Gaa1) subunit
GPAA1 (67 kD) was the first subunit identified in the GPI-T complex.19 It
has a single N-terminal TM domain, a soluble domain, and six C-terminal TM
domains (Figure 1.6).19 GPAA1 shares 25% sequence identity and 57% similarity
with yeast Gaa1.76 It assembles into a stable complex with Gpi16 and Gpi8 in
yeast.18 In human cells, GPAA1 associates with PIG-K, PIG-T, PIG-S and PIG-U
and is essential for transamidase activity.17,85,91 A portion of the soluble domain of
yeast Gaa1 (residues 70-247) was characterized recently using small angle Xray scattering (SAXS) providing a low resolution map of a fragment (residues 70247) of this domain.94
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Figure 1.6: The GPAA1 structure. GPAA1 has one N-terminal transmembrane
domain, a single soluble domain (~323 amino acids) and six C-terminal
transmembrane domains.95 Two N-linked glycosylation sites are found in GPAA1
at Asn203 and Asn517.
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While its exact function is unknown, evidence suggests that GPAA1
recognizes and stabilizes the C-terminal signal sequence of the peptide substrate
through a conserved Pro609 in the last transmembrane helix.85,96,90 Additionally,
photo cross linking studies also support the hypothesis that GPAA1 interacts with
protein substrates for GPI-T. GPI-T from GPAA1 knockout mouse cells were still
capable of generating the thioester intermediate between Gpi8 and a substrate
protein, but this intermediate was not processed to the mature, GPI anchored
protein.91 Combined, these observations are consistent with GPAA1 containing
part of the active site (in addition to Gpi8) and/or a substrate recognition domain.
However, with all these finding, a recent paper claimed that GPAA1 is a M28
peptide synthetase that carry presumably a Zn2+ metal binding site and catalyzes
peptide bond formation between the substrate and the GPI anchor.

1.4.3 The PIG-T (Gpi16) subunit
PIG-T is a 69 kD protein with a large N-terminal hydrophilic region and a
C-terminal transmembrane domain (Figure 1.7).17 A mutation in PIG-T is
connected to a recessive intellectual disability syndrome, which, to our
knowledge, is the only known GPI-T defect associated with a disease other than
cancer.16 In yeast, Gpi16 is co-purified along with GST-Gpi8 and Gaa1; in human
all five subunits co-purify as a complex with GST-PIG-K.5,18 Even though the
exact function of this subunit is not clear, PIG-T is essential for formation of the
carbonyl intermediate between Gpi8 and the protein substrate during
transamidation (see Figure 1.5).17 Some evidence suggests that PIG-T stabilizes
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Figure 1.7: The PIG-T structure. PIG-T has one N-terminal soluble domain
(~506 amino acids) and a single C-terminal transmembrane domain. PIG-T is
connected to PIG-K via a disulfide bond (not shown). PIG-T has three N-linked
glycosylation sites in its soluble domain.
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PIG-K and GPAA1: When PIG-T was knocked out, reduced expression levels of
the other GPI-T subunits were observed.17 PIG-T makes a functionally relevant
disulfide bond with PIG-K through two conserved cysteine residues, Cys92 (in
PIG-K) and Cys182 (in PIG-T), making it the only subunit covalently linked to the
catalytic subunit.86 This linkage is not essential for the formation of the GPI-T
complex, but is important for GPI-T activity.86

1.4.4 The PIG-S (Gpi17) subunit
PIG-S is a 61 kD protein with a large soluble domain in between two
transmembrane regions (Figure 1.8).17 In yeast, Gpi17 is essential for GPI-T
activity, but it does not stably interact with the core GPI-T subunits (Gpi8, Gpi16,
and Gaa1) and its exact function is unknown.89 As observed with PIG-T,
knockout of the PIG-S gene eliminated formation of the thioester intermediate
between PIG-K and the proprotein substrate.17 PIG-S is one of the subunits
replaced by TTA1 and TTA2 in T. brucei (See Figure 1.8).

1.4.5 The PIG-U (Gab 1) subunit
PIG-U was the fifth (and presumably final) subunit identified as a
component of GPI-T (Figure 1.8).5 This 38 kD protein is highly hydrophobic and
has between eight to ten transmembrane regions. Deletion of this gene inhibits
the formation of cell surface GPI anchored proteins.5 Vainauskas and Menon
suggested that PIG-U is more loosely associated with the GPI-T complex than
any of the other subunits, based on differential immunoprecipitation patterns with
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Figure 1.8: Subunits PIG-S and PIG-U are found in human GPI-T (a) and are
replaced by TTA1 and TTA2 in T. brucei (b). PIG-S and TTA1 are not related in
sequence but have topological similarities and both contain two putative
glycosylation sites. PIG-U and TTA2 both have two small soluble domains and
several transmembrane domains however they are topological dissimilar and do
not share sequence similarity.
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digitonin versus Nonidet-solubilized microsomes.90 Although its contribution to
the GPI-T complex is unknown, PIG-U does show weak sequence similarity with
fatty acid elongases suggesting that it may be involved in recognition of the lipid
portion of the GPI anchor.5 PIG-U was the first GPI-T subunit found in human
cancer.4 Like PIG-S, PIG-U is also replaced by TTA1 and TTA2 in the T. brucei
GPI-T (see Figure 1.8).

1.4.6 The TTA1 & TTA2 subunits
Two of the five human GPI-T subunits (PIG-S and PIG-U) are not
conserved across all eukaryotes. In trypanosomes, these two subunits are
replaced by the Trypanosomatid Transamidase 1 (TTA1) and Trypanosomatid
Transamidase 2 (TTA2) proteins (Figure 1.8).74 TTA1 has two transmembrane
helices, one at each terminus. The intervening hydrophilic soluble region is
predicted to face the luminal side of the ER and contain two N-glycosylation
sites. TTA2 contains multiple transmembrane domains and a single soluble
domain. TTA1 and TTA2 do not share sequence homology with any mammalian,
yeast, plant, insect or nematode GPI-T subunits; however orthologs are present
in Leishmania major. TTA1 and TTA2 are linked to each other through a disulfide
linkage and knockout of either of these subunits inhibits the transfer of the GPI
anchor onto its protein substrates.
The relevance of TTA1 and TTA2 to a discussion of GPI-T and cancer is
not immediately obvious. However, these two trypanosomal subunits have
replaced PIG-S and PIG-U, the same two subunits that do not co-purify as part of

	
  
	
  

28	
  
	
  

a robust complex from Saccharomyces cerevisiae.18 Even though we don’t yet
understand the impact of these observations, they do suggest that the roles of
PIG-S and PIG-U in human GPI-T may be peripheral compared to those of PIGK, PIG-T, and GPAA1. In other words, they hint that PIG-K, PIG-T, and GPAA1
may constitute the catalytic core of GPI-T for all species. While this hypothesis
remains speculative, it is likely that these observations will ultimately contribute to
our understanding of human GPI-T function and the roles of these subunits in
cancer.

1.5 GPI-T and cancer
The amplification of oncogenes contributes to human carcinogenesis.97
Chromosomes 8q and 20q are frequently amplified in many cancers including
breast, bladder, ovarian and endometrioid carcinomas.98,99,100,101,102 Out of the
five GPI-T subunits, the genes encoding PIG-U, PIG-T and GPAA1 are localized
in the 20q11, 20q13 and 8q24 chromosome regions, respectively, positions that
are considered hotspots for most cancers.103 The genes encoding PIG-K and
PIG-S are located at 1p31 and 17p13, respectively.103 Simple localization of a
gene within an oncogenic amplicon is insufficient to identify an oncogene.
Amplicons contain multiple genes, not all of which have increased copy numbers
in the corresponding tumors nor are overexpressed to a significant degree.
However, known oncogenic amplicons make useful starting points to identify new
oncogenes and to better understand tumorigenesis.
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The first hint for the importance of GPI-T in cancer was reported by Trink
and colleagues in 2004, with their discovery of the first oncogenic GPI-T subunit,
CDC91L1 (encoding PIG-U) in bladder cancer.4 With this finding, the possibility
of overexpression of other GPI-T subunits in different cancer types came into the
picture. Another critical study showed that breast cancer cells have significantly
elevated levels of cell surface GPI anchored proteins that are more typical of
mesenchymal stem cells than of healthy breast tissue.104 This finding is
consistent with overexpression of one or more GPI-T subunits leading to upregulation of GPI-T catalytic activity as a mechanism for tumor initiation or
invasion.

This

section

will

discuss

our

current

understanding

of

the

overexpression of different GPI-T subunits in different cancer types, at both the
mRNA and protein levels, and their importance as oncogenes or biomarkers. It is
clear that a number of different downstream events can be activated or regulated
by overexpression of different GPI-T subunits.

1.5.1 PIG-U and Cancer
PIG-U was the fifth subunit identified in the GPI-T complex, a hydrophobic
protein that is essential for GPI-T activity.5 Building on the discovery of germline
translocation of the 20q11 chromosomal region in uroepithelial cancer, the
CDC91L1 (PIG-U) gene was characterized for its role in bladder cancer
development.4,105 This gene lies adjacent to the germline translocation site.
Overexpression of PIG-U in mice induced tumorigenesis, providing strong
evidence that this subunit acts as an oncogene.4 Furthermore, forced
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overexpression of PIG-U in cell culture induced an increase in cell growth rate
and enhanced overexpression of proteins known to be GPI anchored. Of
particular interest was the observed overexpression of urokinase plasminogen
activated receptor (uPAR).4 This GPI-anchored protein is a well-characterized
oncogene for most cancers.106,107 Increased STAT-3 phosphorylation was also
observed as a downstream effect of uPAR overexpression, suggesting that
tumorigenicity arises from perturbations in JAK/stat cell signaling.4 In total, this
report suggests that overexpression of PIG-U increases GPI-T activity and
anchoring of substrate proteins although the mechanism by which activity is
increased remains unknown, particularly since PIG-U is not the catalytic subunit
of GPI-T.
A subsequent study concluded that CDC91L1 is not overexpressed in
urothelial cell carcinomas (where 2.4% overexpression of CDC91L1 mRNA was
observed compared to > 30% CDC91L1 amplification in cell lines and primary
bladder tumors.4,108 Finally, a third group assessed a larger data set of bladder
urothelial cell carcinoma. In this study, CDC91L1 mRNA was overexpressed in
30.1% of tumors compared to healthy cells. PIG-U protein overexpression
occurred in 75.3% of tumor samples.109 These differences in overexpression
levels of both mRNA and protein presumably arise from different factors such as
tumor stage, age and gender of the patient, or other environmental factors that
remain poorly understood.
Expression patterns for all five GPI-T subunits were analyzed in 19
different cancer types and compared to healthy tissues from the same organ and
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the same patient using microarray technology.103 Basal level expression of
different subunits varied in different types of healthy tissue.103 PIG-U mRNA was
overexpressed in 60% of colon and ovarian cancer samples versus healthy
tissue.103 In lymph node tumors, PIG-U protein was expressed at moderate to
low levels in 90% of malignant tissues, but was not detectable in the
corresponding healthy tissues. Also a significant increase of PIG-U protein
production was observed in both ovarian and breast cancer cells and
overexpression occurred in 60% of large cell lung carcinoma cells.103 PIG-U was
overexpressed in 42% of breast cancer cells, as well as in prostate cancer.103,110

1.5.2 PIG-T and Cancer
The PIGT gene is also positioned in a chromosomal hot spot
(chromosomal region 20q13.12). With the discovery of PIG-U as an oncogene,
the possibility of other GPI-T subunits as oncogenes, including PIG-T, became
relevant.4,103 Overexpression of PIG-T was first found in human breast cancer. An
increase in PIG-T expression correlated with downstream overexpression and
phosphorylation of paxillin, a known cell invasion related and tumorigenic
protein.110,111,112
In the same microarray report discussed for PIG-U, PIG-T mRNA
overexpression was observed in 60% of uterine, 50% of thyroid and melanoma,
and 30% of breast cancer samples compared to healthy tissues.103 Significant
PIG-T protein overexpression was observed in colon, thyroid, lung and
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pancreatic cancers; overexpression at lower levels also occurred in both
squamous cell carcinoma and lung adenocarcinoma cells.103
A combination of mass spectrometry, separate siRNA inhibition of PIG-T
and GPAA1 expression, and separate overexpression of each of these subunits
led to the identification of nineteen GPI anchored proteins that are specifically
expressed in breast cancer cells and are either poorly expressed or not
expressed in healthy breast tissue.104 Eighteen of these biomarkers are present
in mesenchymal stem cells, suggesting that all or some of these proteins
facilitate dedifferentiation of breast cancer cells. Furthermore, reduction of either
PIG-T or GPAA1 levels by siRNA reduced expression levels of the FOXC2
transcription factor by 80%. Overexpression (by viral infection) of either subunit
increased expression of FOXC2 at both the mRNA and protein levels.104 The
authors posited that overexpression of either PIG-T or GPAA1 affects signal
transduction pathways (presumably by increased expression of a GPI-anchored
cell surface receptor) that leads to increased FOXC2 expression. FOXC2 is
overexpressed in breast and colon cancers and is involved in mitochondrial
biogenesis and increased cell metabolism.104,113
Cigarette smoke extract (CSE) induces cancer formation in head, neck,
bladder and breast cells.114 CSE also induces overexpression of three GPI-T
subunits: PIG-T, PIG-U, and GPAA1.
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1.5.3 GPAA1 and Cancer
Frequent amplification in chromosomal region 8q24 in different cancer
types makes this region a chromosomal hotspot.115,116,117,118 The GPAA1 gene is
in the 8q24.3 region and thus, like PIG-U, is a possible oncogene.73,76
GPAA1 mRNA levels were increased 69% in head and neck squamous
carcinoma and 40% in uterine cancer cells.103,119 Significant overexpression of
GPAA1 protein was observed in ovary and thyroid cells, along with ~40%
overexpression in prostate cancer and 10-20% in lung adenocarcinoma cases.103
PCR-array profiling of 20 pairs of liver tissues (healthy vs. tumor samples)
identified 117 genes with different expression levels, only seven of which were
amplified in hepatocellular carcinoma and both hepatitis B virus positive
carcinoma and hepatitis C virus positive carcinoma.120 GPAA1 was one of these
seven genes. Amplification was observed at both the mRNA (75%) and protein
levels (90%).121
When GPAA1 was overexpressed in breast cancer cells, levels of
phosphorylated

paxillin

also

increased,

thereby

activating

Brk-mediated

phosphorylation and promoting cell invasion that is linked to tumor metastasis
(Figure 1.9).110,112,122 Along with PIG-U and PIG-T, GPAA1 was overexpressed in
the presence of CSE, which led to initiation of paxillin phosphorylation in head,
neck, bladder and breast cancers.114 GPAA1 overexpression led to its
association with the epidermal growth factor receptor (EGFR) and EGFR
phosphorylation in the presence of epidermal growth factor.114 As a
consequence, PIG-T and PIG-U were phosphorylated by EGFR. It was proposed
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that this GPAA1-EGFR interaction and phosphorylation leads to phosphorylation
of paxillin to induce cancer initiation.114 GPAA1 overexpression was observed in
a variety of different cancers that did not correlate with overexpression of other
GPI-T subunits. The connection between GPAA1 and EGFR may explain this
divergence.114 Elevated levels of GPAA1 also increased FOXC2 protein
levels.104,113

1.5.4 PIG-K and Cancer
Human PIG-K is the catalytic subunit of the GPI-T complex.12,20 Compared
to other subunits, PIG-K resides on a different chromosome (1p31.1), in a region
that is frequently lost in various human cancers.123 In breast cancer, PIG-K was
overexpressed in both ovarian (64%) and uterine (67%) cancers.103 However
PIG-K was down-regulated 50% in both bladder and hepatocellular carcinoma
cells and 40% in colon carcinoma cells, based on mRNA levels; similar downregulation was observed at the protein level (40%, 100%, and 40%
respectively).103 In order to understand the reason for diminished PIG-K
expression, all ten PIG-K exons were examined in samples from 45 different
colorectal cancer patients. A single nucleotide polymorphism at position
rs1048575 (outside the coding region), which changed C/C to either G/C or G/G,
was identified that varied with race.124 In contrast, PIG-K was undetectable in
normal lymph node tissues but accumulated in 65% of lymph node cancer
samples.103
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Given the close connections between GPI-T and cancer in general, it is
perhaps surprising that PIG-K, the catalytic subunit of GPI-T, is more likely to be
down-regulated than up-regulated in many cancers. In yeast, depletion of Gpi8
causes changes in actin morphology (depletion of Gab1, but none of the other
GPI-T subunits, showed similar effects).125 These changes offer one possible
scenario for how reduced Gpi8 expression might lead to downstream
tumorigenesis without increasing GPI-T activity and anchoring of oncogenic GPI
anchored proteins.

1.5.5 PIG-S and Cancer
The PIG-S gene resides in chromosomal region 17p13.2, a region lost in
certain cancers.123 However, PIG-S is overexpressed in breast cancer tissues
compared to healthy tissues.103 A significant overexpression of PIG-S protein
was seen in thyroid cancer samples and mRNA levels of PIG-S were amplified
60% in lung, 40% in ovarian and liver, and 50% in thyroid cancers.103

1.6 How does GPI-T subunit overexpression lead to cancer?
Overexpression of each GPI-T subunit has been observed in one or more
cancer types with different frequencies and different patterns. For example, in
breast cancer samples, PIG-T, PIG-U and GPAA1 are commonly overexpressed
compared to healthy tissue. In ovarian tumor samples, PIG-T, PIG-K, and
GPAA1 were overexpressed. In some colon cancer samples, PIG-T is
overexpressed, but PIG-K expression suppressed.103 Table 1.4 highlights some
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Table 1.4: Examples of reported changes in GPI-T subunit expression
(compared to healthy cells of the same tissue).

Cancer Type

PIG-U

Bladder Cancer103,109

↑↑↑

Breast Cancer103,126

↑↑

PIG-T

PIG-K

↑↑

↑

↑

↓↓

Head and neck squamous
carcinoma119
↓↓↓

Hepatitis positive
hepatocellular carcinoma121

↑↑*
↑↑↑

Lymph node cancer103

↑

Lung carcinoma103

↑↑↑

↑↑↑
↑

Melanoma

↑

↑↑↑*

↑

↑↑*

↑↑*
↑

↑↑↑

Pancreas cancer103

↑
↑

↑↑

Squamous cell
carcinoma103

↑

Thyroid cancer103

↑↑*

Uterine cancer103

↑↑↑*
	
  

	
  

↑

↑↑↑*

Hepatocellular carcinoma103

Prostate cancer103

PIG-S

↓↓

Colon cancer103

Ovarian cancer103

GPAA1

↑
↑↑↑

↑↑*

↑↑*
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Symbols are as follows: ↑↑↑ indicates >50% overexpression; ↑↑ indicates 20-50%
overexpression; ↑ indicates 0-20% overexpression; ↓↓↓ indicates >50% downregulation; ↓↓indicates 20-50% down-regulation; * indicates data obtained from
mRNA levels (all other data reflect characterization of protein expression levels).

examples of the patterns of subunit expression observed in different tumor types
and samples.
The five GPI-T genes have the hallmarks of oncogenes, tumor
biomarkers, and potential targets for the development of new chemotherapeutics.
However, a great deal remains to be understood before GPI-T subunits can be
used to detect or treat cancer. For example, how does overexpression of one
subunit induce tumorigenesis? The work described above has led to proposals
for different mechanisms (Figure 1.9). First, and most logically, overexpression of
a GPI-T subunit can lead to increased GPI-T activity and increased presentation
of GPI anchored proteins on the surface of cancer cells.
The observation that PIG-U overexpression increased uPAR cell surface
presentation and Jak/STAT cell signaling supports this hypothesis.4,107 So does
the fact that GPAA1 overexpression in breast cancer correlated with increased
cell surface presentation of 18 GPI anchored proteins involved in cell
dedifferentiation.104 Second, overexpression of GPI-T subunits can cause
perturbations in cell signaling and transcription that facilitate tumor growth.
Evidence is accumulating to support roles for GPI-T in modulating paxillin
phosphorylation and overexpression of the FOXC2 transcription factor.104,114
Neither paxillin nor FOXC2 is GPI anchored so the subunit overexpression
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(c)

PIG-‐T PIG-‐K

PIG-‐S

GPAA1

PIG-‐U

FOXC2

Induces mitochondrial
biogenesis & increased
metabolic activity

Figure 1.9: Proposed mechanisms for how GPI-T may participate in cancer:
(a) Overexpression of uPAR to upregulate the JAK/STAT phosphorylation
pathway; (b) Activation of paxillin phosphorylation; (c) Upregulation of FOXC2
expression and downstream signaling. The solid lines represent pathways that
have more direct experimental support. The dashed lines represent pathways
that likely involve intermediate steps that are currently uncharacterized.
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mechanism that leads to these perturbations is not clear. The apparent
recruitment of EGFR to the GPI-T complex upon GPAA1 overexpression is
perhaps the most intriguing observation.114 This association led to phosphorylate
of both PIG-T and PIG-U.

It isn’t known how these phosphorylation events

impact GPI-T activity, however expression of these different subunits and
recruitment of EGFR correlated with paxillin phosphorylation.114
It is clear from these efforts that changes in GPI-T subunit overexpression
impact the concentrations of different cell surface GPI anchored proteins and
modulate signal transduction. The specific perturbations in GPI-T that lead to
these consequences remain poorly understood. For example, is EGFR involved
in the dedifferentiation of breast cancer after GPAA1 overexpression? Or do the
GPAA1/EGFR interactions induce tumorigenesis via a mechanism that is
different from GPAA1-induced dedifferentiation? And, at a more basic level, how
does overexpression of each subunit impact GPI-T activity? It is easy to
hypothesize that GPI-T activity is up-regulated in all cases, but this hypothesis is
contraindicated by the fact that PIG-K, the catalytic subunit, is actually downregulated in many tumors.
With respect to tumorigenesis and GPI-T, it is clear that we are still looking
at only the tip of the iceberg. Further cell biology studies are needed, in addition
to a careful assessment of the impact of subunit overexpression on GPI-T
activity, which was one of the goals in this dissertation.

	
  
	
  

41	
  
	
  

1.7 Functions of GPI anchored proteins relevant to tumorigenesis
GPI anchored proteins participate in diverse functions including immune
responses,

embryogenesis,

fertilization,

cell

wall

biosynthesis,

signal

transduction, and others.127,128,129,130 The medical relevance of GPI anchored
proteins is clear because specific GPI anchored proteins are crucial for tumor
growth and invasion as well as other diseases like Creutzfeldt-Jakob disease,
bovine spongiform encephalopathy, and African sleeping sickness.4,7,131,132
The following section discusses the physiological functions of a few GPI
anchored proteins in cancer along with their potential relevance as oncogenes,
biomarkers, and therapeutic targets. This section does not represent a
comprehensive list of GPI anchored proteins in cancer. Instead, it is meant to
highlight the different ways that GPI anchored proteins are known to participate
in tumorigenesis and cancer progression. The importance of these proteins in
cancer also implicates GPI-T, or its individual subunits, as targets for the
development of new chemotherapies. The challenge with targeting GPI-T for
cancer treatments, however, is that any suitable drug would likely have to access
the ER to be effective. Thus, GPI-T may prove to be a difficult drug target, but
changes in the expression of GPI anchored proteins in cancers, like those
described below, offer an additional set of potential targets.
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1.7.1 Urokinase plasminogen activated receptor (uPAR)
uPAR belongs to the urokinase plasminogen activating system (uPAS),
which also includes the urokinase plasminogen activator (uPA), and two serine
proteinase inhibitors, plasminogen activator inhibitor-1 (PAI-1) and -2 (PAI-2).
uPAR is a ~60 kD glycoprotein that is GPI anchored.133 It has three domains, D1,
D2 and D3, linked together by conserved disulfide bonds.107 In healthy tissues,
uPAR is expressed at moderate levels; strong expression is seen in tissues
undergoing extensive remodeling.134 uPAR regulates extracellular proteolysis by
binding to uPA and activating plasminogen-generating plasma.135 Because of the
above properties, uPAR is overexpressed in almost all cancer types;
upregulation of uPAR causes downstream changes in a number of different cell
signaling pathways (some of which are described below).106,136,137,138,139,140
Different expression levels of components of the uPA system act as
biomarkers for different cancers and these receptors and enzymes can serve as
therapeutic targets.141,142 The most effective way to use this system is by
inhibiting uPA using small molecule inhibitors or by interfering with the uPA/uPAR
interaction. Small molecules such as 3-amidinophenylalanine negatively affect
the uPA system and thereby limit the invasiveness of head and neck carcinoma
cells, and cervical and breast cancer cell lines. Soluble uPAR inhibits cell
proliferation in ovarian cancer.143,144 Catalytically inactive uPA fragments and
peptide constructs that can be used as antagonists or toxins were also useful in
treating uPAR-activated cancer cells.145,146
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1.7.2 Glypican-3
Glypicans are GPI anchored heparin sulfate proteoglycans that regulate
the activity of heparin binding growth factor.147 So far, six glypicans have been
identified in mammals, all of similar size (60-70 kD).147 Mutations that takes place
in Glypican-3 can cause loss-of-function, leading to Simpson-Golabi-Behmel
syndrome, a rare X-chromosome-linked overgrowth defect.148 The expression
levels of glypicans differ in growth stage and tissue specific manners, however
expression

predominates

during

development

and

in

developmental

morphogenesis.149,150
The ability of glypicans to regulate growth and survival indicates their
relevance in tumor progression. The first relationship between cancer and
glypicans was seen in human pancreatic cancer, where glypican-1 was
overexpressed.151 Glypican-3 is overexpressed in hepatocellular carcinoma and
in the clear cell carcinoma of ovaries.132,152 However, down-regulation of
glypican-3 was observed in breast, lung and ovarian cancer cells.153,154,155 The
high expression levels of glypican-3 in both hepatocellular and ovarian clear cell
carcinoma have led to the evaluation of this protein as a therapeutic target using
cell- and antibody-based immunotherapies with some promising results.156,157,158
Its differential overexpression in different cancers suggests that glypicans can be
used as biomarkers using immunohistochemistry and they may be suitable as
therapeutic targets.
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1.7.3 Folate binding receptor
Two folate binding receptors (FR) are GPI anchored glycopeptides that
have high affinity to folic acid (Kd ~ 1 pM).159 Four different isoforms of FRs are
known (α, β, γ andδ), however only the α and β isoforms are GPI anchored.160,161
FR-α is the most widely studied isomer, which has limited expression levels in
normal tissues but is overexpressed in a variety of cancer cell types including
ovarian, lung, breast and others.162,163,164 Due to its high affinity for folic acid, the
FR/folate interaction has been used in radiopharmacology, chemotherapy, and
magnetic resonance imaging.165,166,167
During the last two decades, folate-based radioconjugates have been
developed to use in PET and SPECT imaging and tested in clinical trials in
patients with folate receptor positive solid tumors.168,169 Several radioisotopes
have been used for PET imaging, including fluorine-18, gallium-68, terbium-152
and scandium-44.170,171,172,173 The EC90 vaccine has been used in folate immune
therapy and is in phase I studies for patients with renal cell cancer.174 Several
folate receptor targets have been synthesized to use in chemotherapeutics. For
example, folate conjugate EC145 is in phase I clinical studies for patients with
refractory tumors.175,176 Overexpression of the folate receptor α in lung cancer
(72% in adenocarcinomas and 51% in squamous cell carcinomas) indicates the
importance of the folate receptor as a therapeutic agent and the need for more
investigation of this GPI anchored protein.162,177
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1.7.4 Prostasin
Prostasin is a serine protease highly expressed in the kidneys, prostate
and lungs.178 It is a GPI anchored protein that acts as a channel activating
protease-1 (CAP-1) and activates epithelial sodium channels, which maintain the
salt and fluid balance in the kidneys.179,180 Prostasin is down-regulated in gastric
and prostate cancer cells but it is overexpressed in pancreatic, breast and oral
cancer cells.181,182 Recently prostasin has been identified as a potential tumor
marker for early stages of ovarian cancer.183 Even though the role of prostasin in
cancer cells is not well understood, the use of prostasin inhibitors such as
protease nexin–1 (PN-1) have been investigated.184

1.8 Dissertation research
GPI anchored proteins play vital roles in different cancers and correlate to
changes in GPI-T expression. Even though the importance of GPI anchored
proteins in cancer is well established, the importance of GPI-T came into the
picture only in 2004 with the discovery of PIG-U as an oncogene in bladder
cancer. Since this discovery, several interesting findings have shown that the
expression levels of different GPI-T subunits are highly variable in different
cancer types and between patients. One key question that needs to be
addressed is how the underexpression of PIG-K or Gpi8, the catalytic subunit,
affects the GPI-T function in a way that promotes tumors. A detailed knowledge
of GPI-T structure and function is needed in order to understand the role of this
enzyme in cancer. To answer this difficulty, I have simplified the complexity of the
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GPI-T core subunits to facilitate studies of this critical enzyme in my dissertation
work. Here we used only the soluble domains of the core subunits to analyze the
structure and function of each subunit alone and with respect to interactions with
other core subunits.
Chapter 2 describes the characterization of Gpi8, the catalytic subunit of
GPI-T. Here we looked at the dimerization of Gpi823-306, the effect of N-linked
glycosylation on Gpi823-306 dimerization, and analysis of single point mutations
along the predicted dimer interface of Gpi823-306 on dimerization. This chapter
showed a robust Gpi823-306 dimerization when overexpressed and purified from
both yeast and E. coli. Also, the N-linked glycosylation didn’t have any effect on
Gpi823-306 dimerization and the single point mutations done on the predicted
dimer interface of Gpi823-306 couldn’t disrupt the dimer completely.
Chapter 3 examines interactions between the three core subunit soluble
domains (Gpi823-306, Gaa150-343 and Gpi1620-551). Using co-immunoprecipitation
and co-purification methods, we demonstrated that each pair of subunits can be
isolated as a heterodimer and that the three soluble domains assemble into a
heterotrimer.
Chapter 4 quantifies the impact of subunit overexpression on GPI–T
activity in vivo. All five subunits overexpressed in cancer in varying levels.
Therefore it is important to look at how each subunit overexpression affect on
GPI-T activity. Here we use invertase reporter assay with three different
Invertase variants having three C-terminal signal sequences to check the GPI-T
activity when each of the core-subunits are overexpressed. For the three variants
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overexpression of each GPI-T subunit showed a pattern of changes in GPI-T
activity.
Chapter 5 concludes this dissertation with a discussion of the interesting
questions about GPI-T that remains unanswered and could be examined in the
future.
Two appendices are included that describe results from smaller, side
projects. Appendix A describes our efforts in the synthesis of peptides and
characterization of GPI-T in vitro assay products using ESI-MS. Appendix B
summarizes our efforts to characterize the tetramer formation with yeast Gpi823306

and Gaa150-343.
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CHAPTER 2
GPI81-306 DIMERIZATION: EFFECTS OF N-LINKED GLYCOSYLATION AND
ANALYSIS OF THE PREDICTED DIMER INTERFACE
2.1 Introduction
Being the catalytic subunit, Gpi8 plays an important role in the GPI-T
complex. Even though Gpi8 is the most well characterized subunit in GPI-T,
questions have been raised over the last five years about the structure and
function of this subunit in terms of stoichiometry and its the catalytic activity.83-84,
92, 185-186

Therefore further characterization of Gpi8 is still required for a complete

understanding of GPI-T to be achieved.
Full-length yeast Gpi81-411 is a 47 kD protein that belongs to the C13
cysteine protease family. It contains a catalytic dyad (His 157 and Cys 199) that
is believed to create a thioester intermediate with the ω-site residue of each
protein substrates for GPI-T (see Figure 1.5). Rosetta software was used to
construct a tertiary model of the soluble domain of Gpi8. This model overlaid
nicely onto the structure of caspase-1 from S. frugiperda, even these two
proteins share only very low level sequence similarity (~6%) (Figure 1.4).83,187
In order to better understand about this protein, yeast Gpi823-306 was first
overexpressed and purified using E. coli to obtain higher levels of protein
expression.83 Here we used only the soluble domain I of Gpi823-306 without its Nterminal signal sequence, according to the Rosetta model. Purified Gpi823-306 was
shown to exist as a mixture of homodimer and monomer, leading to the proposal
that Gpi8 assembles into a homodimer analogous to caspases.83 At this time, we
hypothesize that the monomer was inadvertently formed either because of the
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truncation of this subunit (e.g. the transmembrane domain would further drive
dimerization) or as a result of heterologous expression in E. coli (e.g.
glycosylation would help induce dimerization). This dimerization model was later
questioned by a group of scientists from Singapore, who demonstrated that
Gpi824-334 was monomeric.84 However, this group purified Gpi824-334 by size
exclusion chromatography (SEC), and apparently did not look for the dimer in
their SEC experiment, suggesting that the dimerized fraction might have been
lost during purification.
Here, we set out to more robustly characterize Gpi8 dimerization using
native polyacrylamide gel electrophoresis (PAGE), SEC followed by native PAGE
analysis and electrospray ionization ion mobility separation mass spectrometry
(ESI-IMS-MS). Additionally because GPI-T is a eukaryotic enzyme, we
hypothesized that expression in E. coli might fail to generate robustly folded
proteins, leading to the mixture of monomer and dimer that we observed
previously. Therefore we used S. cerevisiae to homologously overexpress and
purify yeast Gpi81-306. In this case, Gpi8 was overexpressed with its N-terminal
signal sequence (residues 1-22) to facilitate its processing through the secretory
pathway. The above mentioned techniques were also used to analyze the effect
of N-linked glycosylation on the dimerization of Gpi81-306 and to analyze the
predicted dimer interface. Still when Gpi81-306 was expressed in yeast, a mixture
of dimer and monomer was obtained. Dimerization was stable to mutations at the
N-linked glycosylation site indicating that glycosylation does not drive
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dimerization. Mutations at the predicted dimer interface only partially disrupted
dimerization.

2.2 Results
2.2.1 Purification optimization of yeast Gpi823-306 over-expressed in yeast
During canonical protein secretion, proteins translocated into the lumen of
the ER undergo glycosylation and folding with the assistance of chaperones and
enzymes.188 Misfolded proteins undergo ER associated degradation in the
proteosome and folded proteins are transported through COPII (coat protein II) to
their appropriate destinations.188 Full length Gpi8 is located in the ER membrane,
with its soluble active site domain in the ER lumen.
We imagined that the soluble domain I of Gpi81-306, when overexpressed
without its transmembrane domain, might be secreted into the extracellular
medium. To test this idea, yeast Gpi81-306-V5- His6 (in pYES-DEST52 vector,
InvSc1 cell line) was overexpressed in yeast and Ni-NTA affinity purification was
used to isolate Gpi81-306-V5- His6 from the cell pellet and the growth medium. (we
assume that the N-terminal signal sequence, residues 1-22, have been cleaved
from this construct, converting Gpi81-306-V5- His6 into Gpi823-306-V5- His6.
(However, this cleavage has not verified.) Gpi823-306-V5- His6 was not secreted
into the growth medium, however it was isolated from cells in low amounts
(Figure 2.1 (a)).
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Figure 2.1: Gpi823-306-V5- His6 is not secreted into the growth medium. (a)
Anti-V5 blot of an SDS-PAGE gel (12%) showing Gpi823-306 expression levels in
the cell pellet (P) versus the growth medium (M); both after Ni-NTA affinity
purification. Lane 1: molecular weight markers, lanes 2, 4 and 6: purified proteins
from pellets when overexpressed for 12, 18 and 24 hours after induction, lanes 3,
5 and 7: proteins purified from the growth medium after overexpressing for 12, 18
and 24 of induction. Three glycoforms of Gpi823-306 were observed in lanes 2, 4
and 6. Lanes 3, 5 and 7 did not contain any detectible Gpi823-306, indicating that
this protein is not secreted to the growth medium. (b) Confirmation of the
presence of Gpi823-306 using Coomassie stain (left) and anti-V5 blot (right).
Purified yeast Gpi823-306-V5- His6 was used to confirm the presence of Gpi823-306.
The left panel shows a Coomassie stained gel of purified Gpi823-306 (lane 1:
molecular weight markers, lane 2: purified protein) and the right panel shows the
anti-V5 blot of the same protein sample (lane 1: molecular weight markers, lane
2: purified protein). The band corresponding to Gpi823-306 was excised from the
Coomassie stained gel, digested with trypsin, and analyzed by mass
spectrometry. (In collaboration with Dr. Chih-Wei Liu from professor Sarah
Trimpin’s lab.)
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Following purification to homogeneity, the protein band believed to be
Gpi823-306 was excised and treated with trypsin to confirm its identity. In-gel
trypsin digestion and mass spectrometry were conducted by Dr. Chih-Wei Liu in
Prof. Trimpin’s lab. The protein bands were excised and cleaned (see materials
and methods section), followed by the analysis of the samples using LC/MS/MS
(Waters Inc.). The LC/MS/MS results were then uploaded to the Mascot server,
to search for the matching sequences. An ion score was then calculated as the
probability of each sequence compared to the matching sequence. The highest
ion score corresponded to the best matched sequence. All ion scores were
summed to give the protein score for one distinct sequence (Table 2.1, lane 1),
which is proportional to the abundance of the protein in one particular sample.
The band corresponding to Gpi823-306 was identified as a combination of
alcohol dehydrogenase (ADH1, ADH2 and ADH3) and low levels of Gpi823-306
(see both Figure 2.1 (b) and Table 2.1). Also ADH1, ADH2 and ADH3 have over
80% sequence homology. This result was unexpected because the native S.
cerevisiae ADH is not histidine tagged and should not have been purified by NiNTA affinity purification. However, a published report has indicated that
overexpression of ADH occurs when using the GAL1 promoter (as in our vector),
with low levels of glucose.189 ADH has two zinc binding motifs and a molecular
weight of 37 kD which is similar in size to domain 1 of Gpi81-306.95 Since there are
no known interactions between ADH and Gpi8, we believe that ADH was nonspecifically purified by Ni-NTA affinity chromatography. Therefore considering
both the low expression levels of Gpi8 and the presence of ADH contamination,
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Table 2.1: MS/MS analysis of the putative Gpi823-306 protein band indicates
the presence of a contaminant, ADH. Protein scores were calculated using the
probability for each of the sequences and the most abundant protein is ADH1.
Along with ADH, Gpi8 is also present in low quantities.

Protein Score

Protein identification

Description

3417

ADH1

S. cerevisiae

1054

ADH3

S. cerevisiae, Mitochodria

947

ADH2

Kluyveromyces marxianus

763

Gpi8

S. cerevisiae

608

ADH2

S. cerevisiae
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we have restricted our analysis to anti-V5 Western blots to specifically visualize
and analyze protein samples containing Gpi823-306-V5-His6.

2.2.2 Homo-dimerization of yeast Gpi823-306-V5- His6 over-expressed in yeast
versus E. coli
We previously reported that Gpi823-306 forms a mixture of homodimer and
monomer when isolated from E.coli.83 Here we set out to determine whether
more robust dimerization would occur when Gpi823-306-V5-His6 was expressed in
S. cerevisiae and purified using Ni-NTA affinity chromatography. GST-Gpi823-306
was expressed in E.coli and purified by glutathione affinity chromatography for
comparison. Purified proteins were analyzed using native PAGE and anti-GST
and anti-V5 Western blots (Figure 2.2). As observed previously,83 when purified
from E.coli, GST-Gpi823-306 forms a monomer/homodimer mixture (Figure 2.2
(a)). Quantitatively, a higher ratio of dimer to monomer was observed when
Gpi823-306 was purified from S. cerevisiae (Figure 2.2 (b)) compared to that from
E.coli. Additionally, when purified from S. cerevisiae, three Gpi8 glycoforms were
visible. These glycoforms hindered quantitative analysis of the extent of
monomer versus dimer. The presence of dimer was confirmed by comparing
bands to the monomer of Gpi823-306, which was obtained by heating the protein in
sodium dodecyl sulfate (SDS) gel loading dye to denature the protein.
These observations were further corroborated by analyzing GST-Gpi823306

purified from E. coli using SEC followed by native PAGE analysis of the

elution fractions (Figure 2.3).
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Figure 2.2: Yeast Gpi81-306 when overexpressed in E. coli or S. cerevisiae
forms a mixture of homodimer and monomer. (a) Anti-GST blot of a native gel
containing GST-Gpi823-306 when overexpressed and purified from E. coli using
glutathione sepharose affinity purification. Lane 1: molecular weight markers,
Lane 2: GST-Gpi823-306 labels indicate the presence of both dimer and monomer
as labeled. (b) Anti-V5 blot of the native gel of Gpi823-306-V5-His6 overexpressed
in S. cerevisiae and purified using Ni-NTA affinity purification. Lane 1: molecular
weight markers, lane 2: denatured Gpi823-306-V5-His6 (see materials and
methods), lane 3: native Gpi823-306-V5-His6. Glycoforms are visible in both the
monomer and the dimer bands. Both bands highlight the presence of a mixture of
dimer and monomer.
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Figure 2.3: GST-Gpi823-306 purified from E.coli yields a higher amounts of
dimer compared to monomer when analyzed by SEC. Analysis of each SEC
fraction of GST-Gpi823-306 using native PAGE (a) and SDS PAGE (b). (a) An antiGST blot of the native PAGE showing both the dimer and monomer for each of
the SEC fractions. Lane 1: molecular weight markers, lane 2: Denatured protein
sample, lanes 3-7: SEC fractions. (b) The anti-GST blot of the SDS PAGE for
each of the fractions analyzed. Lanes are similar to the top (a) panel.
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Unfortunately, individual peaks representing monomer versus dimer were
not resolved by SEC. Since the expected dimer is 114 kD and the monomer is 57
kD, fractions from the SEC column were analyzed from the corresponding size
range (compared to the SEC marker). Without SEC native gel analysis of the
purified GST-Gpi823-306 (from E. coli) indicates higher amounts of monomer over
dimer. However, when these proteins were injected into SEC and then evaluated,
higher amounts of dimer were visible (Figure 2.3).

2.2.3 The effect of N-linked glycosylation on dimerization of Gpi823-306-V5His6.
N-linked glycosylation is an important post-translational modification that
takes place in eukaryotic proteins that enter the secretory pathway and contain
an aspargine (Asn) residue within an Asn(N)-X-Ser(S)/Thr(T) consensus
sequence (X can be any amino acid other than proline).190 Glycosylation is
important for a wide variety of functions such as protein stability, folding, signal
transduction, proper orientation, cellular trafficking and more.191,192,193,194,195,196,197
According to the UNIPROT database, full-length Gpi81-411 contains two
predicted glycosylation sites at N256 and N346. N23 is also an appropriate
consensus sequence, however, it was not listed as a glycosylation site since it is
present immediately adjacent to the N-terminal signal peptide and so it was not
predicted to be a valid site (Figure 2.4 (a)).75 Therefore only the N256 site lays
within the domain I (Gpi823-306), the region of interest herein. When Gpi823-306-V5His6 was overexpressed and purified from S. cerevisiae, three different bands

	
  
	
  

58	
  
	
  

(a)

(b) 1
N

Gpi8

N23

Gpi8

N256
N346

Lumen

Cytosol

N

N23

2

3

4

95
56

N256

43
34

C

26

Anti-V5, SDS PAGE

C

(c)

1

2

3

4

5

6

7

-

+

-

+

-

95

56
43

34
26

Endo H

+

Anti-V5, SDS PAGE

Figure 2.4: Gpi823-306-V5- His6 has two N-linked glycosylation sites within
the region of our interest. (a) A cartoon representation on the possible
glycosylation sites of Gpi8. The full length Gpi81-411 has three glycosylation sites
at N23, N256 and N346. Domain I contains N23 and N256 glycosylation sites. (b)
Anti-V5 blot of an SDS PAGE gel showing the glycoforms found in Gpi823-306-V5His6 and the N256Q and N256A mutants. Lane 1: molecular weight markers,
lane 2: wild type Gpi823-306-V5-His6 lane 3: N256Q mutant and lane 4: N256A
mutant. Wild type Gpi823-306-V5-His6 shows three bands corresponding to
glycosylation at N23, N256 and the unglycosylated form of this protein. Each
mutant (N256Q and N256A) had two bands consistent with glycosylation at N23
and the unglycosylated form. (c) An anti-V5 blot of the SDS PAGE gel showing
the impact of Endo H treatment on Gpi8 glycosylation. The wild type enzyme and
two mutants were treated with Endo H (see materials and methods). Lane 1:
molecular weight markers, lanes 2, 4 and 6: deglycosylated wild type Gpi823-306V5-His6, N256Q, and N256A, respectively, after Endo H treatment. Lanes 3,5
and 7: wild type Gpi823-306-V5-His6, N256Q, and N256A, respectively, before
Endo H treatment. All seven lanes are from one single blot.
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were observed in the anti-V5 blot (Figures 2.2 & 2.4), suggesting the presence of
two glycoforms and the non-glycosylated protein. The two glycoforms represent
multiple glycoforms at N256 or glycosylation at both N256 and N23.
To evaluate the importance of glycosylation on Gpi8 dimerization, we
mutated N256 to Gln (Q) and Ala (A). When overexpressed in S. cerevisiae, wild
type Gpi823-306-V5-His6 showed three bands in the anti-V5 blot, whereas N256
mutants only had two bands (Figure 2.4 (b)). When the wild type Gpi823-306-V5His6 and its two mutants were treated with Endoglycosidase H (Endo H), an
enzyme that removes N-linked glycans198 all glycoforms condensed into one
deglycosylated band (Figure 2.4 (c)). These results strongly suggest that N23 is
also glycosylated. To examine the effect of N-linked glycosylation on Gpi823-306
dimerization, wild type Gpi823-306-V5-His6, the two mutants, and all Endo H
treated fractions were analyzed using anti-V5 blots by native PAGE along (Figure
2.5). In each gel, the corresponding denatured protein was used as a marker. In
all Gpi823-306 samples, the presence of both dimer and monomer was observed,
indicating that glycosylation is not essential for dimerization.
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Figure 2.5: N-linked glycosylation does not affect Gpi8 dimerization. (a)
Anti-V5 blot of a native PAGE gel of wild type Gpi823-306-V5-His6. Lane1:
molecular weight markers; lane 2: denatured Gpi823-306-V5-His6 or mutant; lane 3:
native Gpi823-306-V5-His6 or mutant; lane 4: native Gpi823-306-V5-His6 or mutant
after treatment with Endo H. Both native forms show a mixture of dimer and
monomer. (b) Anti-V5 blot of a native PAGE gel of the N256Q mutant. A mixture
of dimer and monomer was observed even after treatment with Endo H. Lanes
are the same as in (a) but only with the N256Q mutant. (c) Anti-V5 blot of a
native PAGE gel of the N256A mutant. Results were similar to those in panel a
and b. Lanes are the same as in (a) but with the N256A mutant. The presence of
a mixture of dimer and monomer in wild type Gpi823-306-V5-His6 and both mutants
independent of Endo H treatment indicates that N-linked glycosylation does not
affect dimerization.
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The Oligomerization states of the N256Q and N256A mutants were also
examined by SEC (Figure 2.6). Purified N256Q and N256A samples were
injected into the SEC column. Fractions were analyzed by native PAGE and SDS
PAGE. Both N256Q (Figure 2.6 (a)) and N256A (Figure 2.6 (b)) contained a
mixture of dimer and monomer consistent with the gel analyses shown in Figure
2.5.
Additionally, ESI-IMS-MS was used to confirm the formation of the dimer
in both Gpi823-306-V5-His6 and the N256Q and N256A mutants. ESI-IMS-MS is
ideal for this type of analysis because ions can be separated based on size
(shape) and mass.199,200,201,202,203 Nevertheless, it proved challenging to analyze
the dimer and monomer of Gpi823-306 because of their higher molecular weights
(unglycosylated dimer: 74 kD, unglycosylated monomer: 37 kD). Glycosylation of
this protein, yielding the glycoforms shown in Figure 2.5, further complicated the
analysis. Spectra were collected and analyzed in collaboration with Prof. Sarah
Trimpin and of Dr. Ellen Inutan (Figure 2.7). The monomer and dimer mixtures
were also examined by ion mobility separation for Gpi823-306-V5-His6 and the
N256Q and N256A mutants. Ni-NTA affinity purified proteins were buffer
exchanged with ammonium acetate (see materials and methods for details) prior
to analysis. Samples were injected onto the Synapt G2 mass spectrometer for
ESI-IMS-MS analysis. Two dimensional plots of m/z vs drift time were
constructed for each protein and are shown in the top panels of Figure 2.7 (a),
(b) and (c). The middle and bottom panels show mass spectra that can be
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Figure 2.6: SEC analysis confirmed N256 mutagenesis does not affect
dimerization. Anti-V5 blots of the native PAGE gel (top panel) and SDS PAGE
gel (bottom panel) of SEC fractions for the N256Q mutant (a) and the N256A
mutant (b). Concentrated SEC fractions were analyzed using native PAGE,
which shows the presence of both dimer and monomer. Lane 1: molecular weight
markers, lanes 2-9: SEC fractions. Both mutants show dimer and monomer
consistent with the conclusion that N-linked glycosylation is not required for Gpi8
dimerization.
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Figure 2.7. ESI-IMS-MS analysis to characterize the monomer and dimer
forms of Gpi823-306-V5-His6 and N256Q and N256A mutants. ESI-IMS-MS
analysis of (a) wild type Gpi823-306-V5-His6; (b) the N256Q mutant; and (c) the
N256A mutant. In each case, the top panel shows a 2-D plot of m/z vs. drift time.
Charge states corresponding to the monomer and dimer are noted. The middle
panel shows an analysis of the mass spectrum from the dimer region in panel
(a). The bottom panel shows the mass spectrum from the monomer region in (a).
See Table 2.2 for additional analysis.	
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tentatively assigned as dimer and monomer ion clusters (boxed in panels a, b
and c).
Different charge states were observed that are also consistent with
separation of monomer and dimer for all three proteins (summarized in Table
2.2). However, presumably because of the higher molecular weights of the dimer
and monomer and the different glycosylation states, broad peaks were observed
and the ions were of very low abundance. Nevertheless, deconvolution of
different ion clusters yielded interpretable molecular masses for the N256Q and
N256A mutants. Using the masses calculated for the two mutants, the size of the
glycans on N256 in wild-type Gpi823-306-V5-His6 was calculated to be ~3000
g/mol (Table 2.2, Figure 2.7). These results are preliminary, given the low
abundance of the observed ions. Efforts to improve ionization have been
unsuccessful.

2.2.4 Predicted dimerization interface analysis using single point mutations
Activation of caspase 1, a cysteine protease, plays an important role in
innate immune response.204 Inactive monomeric pro-caspase-1 is activated
inside the cell, after undergoing a process of dimerization and auto-proteolysis.205
Structural similarities between	
  our Rosetta model of	
  domain 1 of Gpi8 (Gpi823-306)
and S.	
  frugiperda (Figure 1.4) led us to hypothesize that Gpi8 would also exist as
a dimer.83 We constructed a crude model of the Gpi823-306 dimer by overlaying
the Rosetta model of Gpi823-306 onto the S. frugiperda caspase-1 dimer structure
(Figure 2.8 ) to predict the dimer interface.
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Table 2.2: Summary of the observed charge states for Gpi823-306-V5-His6	
  and
the N256Q and N256A mutants. Molecular weights were calculated from the
different charge states for each protein’s monomer and dimer using the m/z
values assigned to each broad peak by the Drift Scope software. The X denotes
changes in mass that presumably arise from glycosylation at N256.

Calculated

Observed

MW (Da)

MW (Da)

20+, 21+,22+,23+,24+

74255

74321

12+,13+

37127

37125

20, 21+,22+,23+,24+,25+,26+

74141

74291

N233A monomer

12+,13+,14+

37070

37097

Wild type dimer

24+,25+,26+

74227 + 2X

80626

Wild type monomer

13+,14+,15+

37113 + X

39921

Protein complex

N233Q dimer
N233Q monomer

N233A dimer

Observed charge states
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Figure 2.8: Dimer of Rosetta modeled Gpi81-360 created using caspase-1
dimer.
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Figure 2.9: Single point mutation analysis on the predicted dimer interface.
Each image is of an anti-V5 Western blot of native PAGE gels of each of the
seven mutants: (a) Y168A mutant, (b) Y184A mutant, (c) F187A mutant, (d)
P190A mutant, (e) H249A mutant, (f) H253A mutant and (g) F275A mutant. (h) is
the wild type Gpi823-306-V5-His6 for the comparison. For each gel, lane 1:
molecular weight markers; lane 2: denatured protein; lane 3: native protein. For
some images (F187A, P190A, H249A, H253A, and F275A), intervening lanes
from the blot were removed for clarity. These changes are indicated by the
presence of a white space separating the different lanes. The complete,
unadulterated blots are included in an appendix (Appendix C, Figure C.1) at the
end of this dissertation.
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Seven single point mutations were created by Megan Ehrenwerth at the
predicted dimer interface. After overexpression and purification from S.
cerevisiae, each point mutation was analyzed using native PAGE (Figure 2.9).
The glycoforms hindered our ability to quantify the amount of dimer and
monomer for each mutant. However, qualitatively, different ratios of dimer to
monomer were present for the different mutants. None of the	
   point mutations
completely disrupted Gpi823-306 dimerization. However, the	
   P190A and H253A
had the largest effects (Figures 2.9 (d) and	
   (f)). Molecular weight markers and
denatured proteins were used as controls.

2.3 Discussion
All the experiments described herein were conducted with Gpi823-306 that
had either been expressed in E. coli (GST-Gpi823-306) or in S. cerevisiae (Gpi823306-V5-His6).
306

Results confirming our earlier findings and clearly show that Gpi823-

assembles into a homodimer.2 Gpi8 dimer was observed by native PAGE and

SEC. SEC analysis demonstrated that dimer predominates in this mixture. This
was for Gpi823-306 that had been purified from E. coli using glutathione sepharose
affinity purification (Figure 2.2 & 2.3) as well as for the N256 mutants of Gpi823306-V5-His6

mutants that were overexpressed in S. cerevisiae and purified using

Ni-NTA affinity purification (Figure 2.5 & 2.6). These results strongly suggest that
the dimer to monomer ratio observed in vitro depends on the protein’s
surrounding environment. However, complete dimerization was not observed
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with any samples, suggesting that dimerization might be further driven by domain
II or the transmembrane domain, which were deleted in our constructs.
As discussed, full-length yeast Gpi81-411 contains three possible
glycosylation sites: N23, N256 and N346. However, N23 is immediately adjacent
to the N-terminal signal sequence and so it was predicted that this site would not
be glycosylated. The work presented herein represents the first efforts to
characterize the N256 glycosylation site in terms of protein expression, stability,
and its possible participation on dimerization. The elimination of N-linked glycans
at 256, either by mutagenesis or Endo H treatment, did not eliminate
dimerization, demonstrating that glycosylation and dimerization are separate,
disconnected events. The results from this analysis also gave the first indication
that N23 is glycosylated even though it is adjacent to the signal sequence.
Presumably, glycosylation occurs prior to cleavage of residues 1-22 by signal
peptidase. However, N-terminal signal sequence cleavage was not confirmed in
this work.
None of the single point mutations that were made at the predicted dimer
interface didn’t completely dimerize (Figure 2.9). The P190A and H253A mutants
noticeably disrupted dimerization in favor of monomer. It is possible that the
structural changes introduced by these single point mutations are insufficient to
completely disrupt dimerization. Analyses of double and even triple point
mutations are expected to shed further light on this question.
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2.4 Materials and methods
2.4.1 Buffers and solutions
Phosphate buffered saline (PBS): 10 mM Na2HPO4, 1.8 mM KH2PO4, 140
mM NaCl, 8.7 mM, pH 7.3. GSH elution buffer: 100 mM reduced glutathione
(GSH), 50 mM Tris HCl, pH 8.0. Lysis buffer: 50 mM NaH2PO4, 300 mM NaCl, 10
mM imidazole, 5% glycerol, pH 7.4. Wash buffer: 50 mM NaH2PO4, 1 M NaCl, 50
mM imidazole, 5% glycerol, pH 7.4. Elution buffer: 50 mM NaH2PO4, 300 mM
NaCl, 300 mM imidazole, 5% glycerol, pH 7.4. Tris glycine: 25 mM Tris base, 200
mM glycine, pH 8.3. 10X transfer buffer: 0.4 M glycine, 0.5 M Tris base, 13
mM sodium dodecyl sulfate (SDS). 1X transfer buffer: 10X transfer buffer was
diluted to 1X in 20% aqueous methanol. Tris-Buffered Saline and Tween 20
(TBS-T): 10 mM Tris HCl, 150 mM NaCl, 0.05% Tween, pH 7.5). SEC buffer: 50

mM NaH2PO4, 300 mM NaCl. Minimal medium (4X Sc-ura): 26.8 g Yeast
nitrogen base, 6.4 g dropout mix, 0.4 g each adenine, leucine, tryptophan and
histidine in 1L of water and sterile filtered before use.

2.4.2 Over-expression and purification of yeast Gpi823-306 from E. coli
Plasmid pJLM008 (encoding GST-Gpi823-306) was transformed into
BL21(DE3) RIL Codon Plus cells (Stratagene).83 Protein overexpression was
carried out with an overnight culture (30 mL) which was grown at 37 °C in Luria
Bertani (LB) medium, and used to innoculate 1 L of LB medium that had been
supplemented with 50 µg/mL ampicillin (Sigma-Aldrich). This culture was grown
at 19 °C to an OD600 of 0.4-0.5, and then induced with 1 mM isopropyl-γ-D-1	
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thiogalactopyranoside (IPTG, Gold Bio Inc). Cells were pelleted after two hours
post-induction and stored at -80 °C until ready for use.
All purification steps were conducted at 4 °C unless otherwise noted. Cell
pellets were resuspended in 15 mL PBS supplemented with 15 µL
phenylmethanesulfonylfluoride (PMSF, from a saturated solution in isopropanol),
and one quarter tablet of protease cocktail inhibitor (Roche). The suspension was
lysed using an ultrasonic cell disrupter (Microsone) with six pulses for 20 sec
each a power of 4 with 40 sec rest period in ice in between each pulse. The
lysate was spun down at 14,000 rpm for 1 hr in a Beckman JA-20 rotor. The
supernatant was supplemented with 500 µL (bed volume) pre-washed
glutathione sepharose fast-flow resin (GE-Amersham Biosciences). The cell
lysate supernatant and resin mixture was incubated for 1 hr at room temperature.
The resin was washed ten times with 5 mL PBS each time. The expressed
protein was eluted from the resin by treatment with 2 mL GSH elution buffer for
10 minutes at room temperature. The eluted protein solution was removed from
the resin and concentrated to 250 µL. Elutions were loaded directly onto a 12%
SDS-polyacrylamide gel for analysis before they were used for further
subsequent experiments.

2.4.2 Over-expression and purification of yeast Gpi823-306 from yeast
All plasmids encoding for wild type Gpi823-306-V5-His6, and the nine
mutants studied herein (N256Q, N256A, Y168A, Y184A, F187A, P190A, H249A,
H253A and F275A) were inserted into the pYES-DEST52 destination plasmid
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using Gateway cloning technology (Invitrogen). These constructs were prepared
by Megan Ehrenwerth. Briefly, the gene fragment coding wild type was amplified
from genomic DNA using two primers flanking with AttB regions on either side.
The resultant gene product was inserted into a donor vector (pDONR221)
following the BP reaction according to the manufacturer’s instructions
(Invitrogen). This insert	
   was sequenced in its entirety. The insert was then
transferred into the destination vector (pYES-DEST52) using the LR reaction
according to the manufacturer’s instructions. This plasmid introduced the Cterminal V5 and six histidine tags	
   onto Gpi81-306.This plasmid was used as the
parent plasmid to create all the nine mutants using QuikChange site directed
mutagenesis (Qiagen). The complete insert was resequenced after consruction
of each mutant.
Plasmids were then transformed into the S. cerevisiae strain, INVSC1
(Invitrogen) using standard yeast transformation protocols (Invitrogen). In order
to overexpress Gpi823-306 and each of the different mutants, an overnight culture
(50 mL) was grown at 30 °C in Sc-Ura (minimal medium that lacks uracil) and 1%
glucose. This culture was used to inoculate 1 L of Sc-Ura medium with 1%
galactose in a 4 L flask. The culture was incubated at 30 °C. Cells were
harvested after 12 hours and the final OD600 was noted for use in during
purification.
All purifications were conducted at 4 °C. Typically, a cell pellet from a 4 X
1L growth was resuspended in 10 mL lysis buffer and lysed using glass beads
using a bead beater (Invitrogen), for 8X30 s pulses with 30 s rest periods in ice in
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between pulses. The lysate was centrifuged at 3000 rpm for 10 min to remove
the cell debris and glass beads and the supernatant was centrifuged for 1 hour at
14,000 rpm in a Beckman JA-20 rotor. The filtered, clear supernatant was
passed through a 1 mL Ni-NTA high trap column (GE Health care) followed by
wash steps with 5 column volumes of lysis buffer and 50 column volumes of
washing buffer. Finally, the protein was eluted using 5 mL of elution buffer and
the eluted fraction was concentrated to 100 µL. The fractions were analyzed
using 12% SDS-PAGE gel and other techniques.

2.4.3 Analysis of the oligomerization state of Gpi823-306 and its mutants by
native PAGE and Western blots
All proteins were analyzed via an 12% SDS-PAGE or 10% native PAGE
gels. Proteins were kept for 30 min on ice prior to loading onto the native gel.
Electrophoresis was carried out with a 10% native polyacrylamide gel (39:1
Acrylamide:bisacrylamide, at pH 8.8) in tris-glycine buffer for 3 hours at 4 ºC at
100 V. Bands were visualized by Western blot using an anti-V5 antibody (SigmaAldrich).
For all Western blots, the proteins were transferred to the membrane
(Immobilon-FL, Millipore) as follows:. The membrane was soaked in 100%
methanol for 5 min and was transferred into 1X transfer buffer and incubated for
15 mins. For native PAGE 0.15% W/V SDS was added to the1x transfer buffer.
The gel was also put in the 1X transfer buffer with the membrane for 15 min. Six
blotting papers were cut to the same size as the gel and were immersed in the
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same buffer prior to the transfer. A semi-dry Western blot apparatus (Thermo
Scientific) was used for the transferring of proteins from the gel to the membrane.
Three blotting papers were placed on the anode plate followed by the gel,
membrane and another three blotting papers carefully without introducing any air
bubbles. One gel (8.5 cm X 10 cm) was transferred to the membrane for 30 min
at 200 mA.
The transferred membrane was incubated for two hours or overnight in
5% milk in TBS-T prior to incubation with the primary anti-V5 antibody (SigmaAldrich, 0.5 µg/mL in 1% BSA) or the anti-GST antibody (Anaspec, 0.5 µg/mL in
1% BSA) for 2 hr. The membrane was washed 3X with 50 mL TBS-T incubating
for 5 min each time. The membrane was then incubated with anti-mouse IgG
Hilyte Plus 647 (Anaspec, 0.5 µg/mL in 1% BSA) for 1 hr. the membrane was
washed again 3X with 50 mL TBS-T with an incubation of 5 min each time and
then the blot was visualized using a Typhoon 9210 (Red 633 nm excitation laser,
670 nm emission filter).

2.4.4 Analysis of Gpi823-306 protein secretion to media in yeast
Cells were grown at 30 ºC as described above. For each time point, a 500
mL aliquot of the cell culture was removed. Cells were harvested at 3500 rpm for
5 min using a Beckman F-500 rotor. The medium was transferred to a 1 L flask
and NaH2PO4 and NaCl were added to final concentrations of 50 mM and 300
mM respectively. The pH was adjusted to 7.0 and one half of a protease cocktail
inhibitor tablet (Roche) was added to inhibit any proteolytic activity. A precipitate
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formed as the pH was adjusted. The mixture was filtered using a 0.2 µm filter and
the precipitate was discarded (after verification that it did not contain Gpi8 by
SDS-PAGE, data not shown). The filtered medium was treated with Ni-NTA resin
as described above to purify any secreted Gpi823-306. For comparison, Gpi8 was
also purified and analyzed from cell pellets.

2.4.5 Removal of glycans using Endo H
Purified Gpi8 and mutant samples were treated with Endo H to remove
any N-linked glycans. For 30 µL of a protein sample, 0.5 µL of Endo Hf (1000
U/µL, Invitrogen) were added. The digestion was carried out for 2 hours at 30 ºC.
Proteins were incubated at 4 ºC for at least 30 min prior to analysis by native
PAGE.

2.4.6 Evaluation of dimers using size exclusion chromatography (SEC)
A sample of 100 µL of protein (~50 µM) was buffer exchanged with SEC
buffer, filtered using a 0.22 µm filter, and injected onto an ultra high resolution
SEC column (14 mL, Waters) using a BioRad FPLC system. The column was run
with 3X column volume with a flow rate of 0.25 mL/min or 0.3 mL/min. Fractions
were collected, concentrated and analyzed using 12% SDS-PAGE and 10%
native PAGE followed by corresponding blot analysis as described above. A gel
filtration standard (100 µg, SEC marker, BioRad) was used to generate a
standard curve.
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2.4.7 Use of ESI/IMS/MS to evaluate dimer formation by Gpi823-306
Samples for mass spectrometric analysis were quantified using a Bradford
assay (BioRad). Each protein was diluted to a concentration of 5 pmol/µL in 25
mM ammonium acetate buffer with 10% methanol for the analysis by the ESIIMS-MS using a SYNAPT G2 HDMS from Waters Inc. Each sample was injected
at a flow rate of 10 µL/min and drift time and m/z (mass to charge ratio) data
were collected for 20 min. Driftscope 2.1 (Waters) was used to visualize the 2D
plot of drift time vs m/z ratio using a black background and hot metal color code
for the third dimension (ion intensity). The data were further processed by
extracting mass spectral information for the ion peaks of interest. The spectra
were adjusted one time using the Savitzky-Golay smoothing method with a value
of ± 10. Baselines in all spectra were subtracted to provide a baseline level close
to 0%.

2.4.8 In-gel trypsin digestion for protein confirmation
Protein bands were excised from the gel manually, and washed several
times with destaining buffer (10% Acetic acid. 45% methanol and 45% water) to
remove the Coomassie stain. The gel was then cut into small pieces and washed
twice for five minutes each time with 50 µL of 50% acetonitrile (ACN) in water.
Next, the pieces were washed in 50 µL of 200  mM NH4HCO3. The gel pieces
then were shrunk with 100% ACN until they turned white and were dried for 5  min
in an vacuum evaporator (Genevac).
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The following steps as well as acquiring spectra were done by Dr. ChihWei Liu from Prof Sarah Trimpin’s lab. The gel pieces were rehydrated in 15 µL
of 50  mM NH4HCO3 at 37  °C for 4  min prior to trypsin digestion. An equivalent
volume (15 µL) of 20 ng/µL trypsin (Trypsin Gold, Promega) in 50  mM NH4HCO3
was added to the gel pieces, and they were incubated at 37  °C for at least 16  h
for complete digestion. The digests were extracted using 0.1% formic acid in
50% ACN. All extracts were dried and dissolved in 50% ACN:water with 1%
formic acid and analyzed using (LC/MS/MS). The resultant mass spectra were
uploaded into the Mascot server to analyze proteins.
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CHAPTER 3
CO-EXPRESSION AND CHARACTERIZATION OF THE SOLUBLE DOMAINS
OF CORE SUBUNITS OF GPI-T

3.1 Introduction
Gab1 was the first subunit of GPI-T discovered to be oncogenic,
highlighting the importance of this enzyme in cancer.206 However, the complexity
of the membrane-bound GPI-T enzyme has hindered progress towards
understanding how it functions. In 2001, the Conzelmann group discovered that
the full-length GPI-T core subunits, Gpi8, Gpi16 and Gaa1, could be co-purified
as an intact complex.18 Even though Gpi17 and Gab1 are also essential for GPIT activity, they do not form a stable complex with Gpi8, Gpi16, and Gaa1 in
yeast.89 Unfortunately, 10 years later, scientists still have not determined the
function of each subunit or the stoichiometry of the complex. These types of
results would be of general interest	
   because of this enzyme’s medical and
scientific importance. Also, development of a facile assay to investigate GPI-T
activity has proved to be challenging.
In order to understand the structure and organization of the GPI-T
subunits, we want to determine the stoichiometry of each subunit in the GPI-T
complex. Evidence suggests that GPI-T contains more than one copy of each
subunit.18,187 We focused only on the core heterotrimeric GPI-T subunits, Gpi8,
Gpi16, and Gaa1. Our lab has demonstrated dimer formation of the soluble
domain of Gpi823-306 and several other labs have observed that GPI-T is
significantly larger (440-660 kD) than the sum of the molecular weights of the core
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subunits (186 kD, not considering the impact of glycosylation).18,83,85 Combined,
these observations suggest that GPI-T is at least a Symmetrical dimer, perhaps
further modified with different glycoforms. The possibility that GPI-T is a dimer
cannot be entirely ruled out at this point. Despite these observations by us and
others, our evidence for dimerization of Gpi823-306 was questioned recently, in
favor of Gpi8 existing as a monomer.84 In response, in chapter 2 of this thesis,
we further characterized the dimer of Gpi823-306 when overexpressed and purified
from both yeast and E. coli.
The approach we used in Chapter 2 eliminated the complexities
introduced by working with the full-length, membrane-soluble subunits. The native
transmembrane (TM) regions Gpi8 (1 TM), Gpi16 (1 TM), and Gaa1 (6 TMs)
make it difficult to purify and analyze these subunits. Therefore, as in chapter 2,
we used molecular modeling and TM domain predictions to focus only on the
soluble domain regions of these subunits, i.e. Gpi81-306, Gaa150-343 and Gpi16183,207
551.

As a precursor to characterizing the stoichiometry of these subunits, we

first looked at the assembly of each soluble domain into heterodimeric and
heterotrimeric complexes using co-immunoprecipitation studies. In this chapter
we show that each possible pair of these soluble domains assemble into stable
isolable heterodimeric complexes. Additionally, we show that the heterotrimer
containing at least one copy of Gpi823-306, Gaa150-343, and Gpi1620-551, can be
purified by tandem affinity purification (TAP), laying the foundation for future
studies to characterize the stoichiometry of this complex. This complex was
tested initially for GPI-T activity using an in vitro assay under development in our
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lab (Appendix A). We observed an increase in fluorescence over time, even in the
absence of the nucleophile hydroxylamine. Further studies are underway to
characterize the catalytic activity of this soluble core complex as well as to
evaluate its stoichiometry.	
  
	
  
3.2 Results
3.2.1 Plasmid design and construction
Yeast Gpi8 contains a larger luminal domain (residues 23-380) that was
used to create a model using Rosetta software.75,208 (In full-length Gpi8, residues
1-22 contain the N-terminal ER localization signal sequence, residues 377-397
contain the TM domain, and residues 398-411 represent a short cytoplasmic
peptide.)75 The model was built with two domains, domain I (the caspase-like
domain, residues 23-306) and domain II (a smaller domain, residues 307-376)
(Figure 3.1).83 The overlay of domain I to that of caspase-1 from Spodoptera
frugiperda led us to conclude that domain I would likely be sufficient for
dimerization studies (Figure 1.4). Indeed, our previous publication83 and the
results in chapter 2 clearly demonstrate that domain 1 assembles into a
homodimer.
Similar to Gpi8, Rosetta produced a plausible model for Gaa1, taking into
account only this subunit’s large soluble domain (50-343 residues) (Figure 3.1).
(Full-length Gaa1 contains six TM domains; one is N-terminal (residues 20-40)
and the remaining five are C-terminal (residues 357-598)).75 After expression, the
N-terminus of wild-type Gaa1 lies in the cytosol. Thus, to express our
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(a)

(b)

pYES-DEST52
Ura marker

Gpi81-411

pAG305
Leu marker

Gpi81-306-V5-His6

Gaa11-614

CPY-Gaa150-343-TAP

(c)

pAG414
Trp marker

Gpi161-551-HA

Gpi161-610

	
  

	
  

Figure 3.1: Rosetta modeling and design of soluble domain constructions
to overexpress Gpi81-306, Gaa150-343 and Gpi161-551. In all three panels, a
cartoon is shown for each full-length subunit (left) followed by a cartoon of the
soluble domain construct (or constructs) studied herein. See the accompanying
text for additional information about the plasmids used to express these vectors.
(a) A Rosetta model of the soluble domain I of Gpi8 (blue) is shown. Building
from this model, we cloned the portion of the gpi8 gene coding residues 1-306
into the pYES-DEST52 vector. (b) A Rosetta model of the soluble domain of
Gaa1 (red) is shown. Gaa150-343 was cloned into the pAG305-TAP destination
vector. After N-terminal processing, this vector produces Gaa150-343-TAP. (Note:
Another Gaa1 construct was also used but proved significantly less essential so it
is not shown here. See text below for details). (c) A useful Rosetta model was not
obtained from our modeling efforts. Gpi161-551 was cloned into the pAG414-HA
expression vector. After processing, this plasmid is expected to produce Gpi1620551-HA.
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truncated version with processing through the ER, we introduced the vacuolar
protein carboxypeptidase Y (CPY) signal sequence207 to the N-terminus of
Gaa150-343.
The soluble domain of Gpi16 (residues 1-551) was similarly analyzed with
Rosetta after eliminating the single, predicted C-terminal TM domain (Figure 3.1).
Unfortunately, the model returned by Rosetta was not strong. These Rosetta
analyses were conducted by Prof. Tamara Hendrickson, Dr. Jennifer Meitzler, Dr.
Yug Varma, and Megan Ehrenwerth. 83,207
Dr. Meitzler, Dr. Varma and Ms. Ehrenwerth also constructed the original
plasmids for the overexpression of these soluble domains. These plasmids are
described in detail below. Plasmids were constructed using Gateway cloning
technology. Gpi81-306 and Gpi161-551 were cloned with their native N-terminal
signal sequences; Gaa150-343 was cloned with the CPY signal sequence
appended onto its N-terminus. Each gene was initially put into the pDONR221
entry vector (Invitrogen). The resultant donor vectors were used to transfer these
genes into the desired destination vectors as outlined in Figure 3.1. Destination
vectors were selected to contain three different, compatible selection markers (for
co-expression studies) and for the tags that they would append onto each
subunit. Protein expression is induced with galactose with all three final
destination vectors used herein.
Gpi81-306 was transferred into pYES-DEST52 (Invitrogen) to append V5
and His6 tags onto the C-terminus of this protein. These tags were used for
immunoblotting and visualization. The pYES-DEST52 vector contains a Ura
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selection marker. Gpi161-551 was transferred into pAG414-GAL (Addgene), which
adds a C-terminal HA tag for immunoblotting experiments. This vector contains a
Trp selection marker.
CPY-Gaa150-343 was transferred into either pAG414-GAL, which appends a
C- terminal HA tag and contains Trp selection marker, or into pAG305-GAL
(Addgene), which adds a C-terminal TAP tag and contains a Ura marker. As
described below, challenges arose when expressing Gaa1 from the pAG414-GAL
vector. Consequently, all subsequent experiments used the pAG305-GAL vector
coding for Gaa150-343-TAP.

3.2.2 Gaa150-343-HA binds to Ni2+ and Co2+ resin.
The characterization of Gpi823-306 and Gaa150-343 were conducted using
proteins purified from InvSc1 cells, an S. cerevisiae cell line. Initial experiments
(conducted by Dr. Jennifer Meitzler) characterized yeast His6-Gaa150-343 alone
and with GST-Gpi823-306 after overexpression in and purification from E. coli.
Several observations were made, namely that expression of His6-Gaa1 alone is
toxic to E. coli and that the low levels of His6-Gaa150-343 that were present could
be co-purified with GST-Gpi823-306 by glutathione affinity chromatography.207,209
To better characterize this heterodimeric complex, we switched from E. coli to S.
cerevisiae. The plasmids encoding GPY-Gaa150-343-HA and Gpi81-306-V5-His6
were transformed individually or together into InvSc1, S. cerevisiae and were
overexpressed using galactose induction. Co-purification studies were initially
carried out with Ni-NTA affinity purification, to determine whether or not
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purification of Gpi823-306-V5-His6 would result in co-purification of Gaa150-343-HA,
confirming what Dr. Meitzler had seen when variations of these two constructs
were co-expressed in E. coli. Unexpectedly, after purification, Western blots with
α-HA antibody demonstrated that Gaa150-343-HA was purified by Ni-NTA affinity
without co-purification of Gpi823-306-V5-His6 (Figure 3.2 (a)). A control experiment
was conducted with Gpi823-306-V5-His6 in the absence of Gaa1. In this case,
Gpi823-306-V5-His6 was purified as expected. Further analysis revealed that the
purification of Gaa150-343 was not due to interactions with Gpi81-306; instead, this
protein showed affinity for Ni-NTA resin (lane 2 of Figure 3.2 (b)) and also with
Co2+ resin (Figure 3.2, lanes 3-7). These results were surprising because our
Gaa150-343 construct did not contain a His6 tag. Sequence alignments with fulllength Gaa1 (not shown) suggest that it is an M28 type aminopeptidase with one
metal binding site, presumably for Zn2+.186 Perhaps its ability to bind to Ni2+ and
Co2+ resin arises from this metal binding site. Because of this unexpected
obstacle, we reversed our approach and used an anti-HA antibody to examine
Gpi823-306-V5-His6 and Gaa150-343-HA interactions by co-immunoprecipitation
analyses.
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Figure 3.2: CPY-Gaa150-343-HA can be purified by Ni2+ and Co2+ resin without
a His6 affinity tag. (a) Co-purification of CPY-Gaa150-343-HA and Gpi823-306-V5His6 using Ni-NTA affinity purification. Top panel: An anti HA blot to confirm the
presence of Gaa1. Bottom panel: An anti-V5 blot to confirm the presence of
Gpi8. For both panels, lane 1: Gpi823-306-V5-His6 alone; lane 2: Co-purification of
CPY-Gaa150-343-HA and Gpi823-306-V5-His6. (b) Results from a mock purification
of Gaa150-343-HA using Ni-NTA resin. Cell lysate containing overexpressed CPYGaa150-343-HA were incubated with Ni-NTA resin. The results of this purification
were examined by Western blot using an α-HA antibody. The lanes in this blot
are as follows: lane 1: molecular weight markers; Lane 2: Gaa150-343-HA purified
by Ni-NTA affinity chromatography; lanes 3-7 show the results of this mock
purification using Co2+ resin; lane 3: cell lysate; lane 4: flow through; Lane 5:
wash; Lane 6: eluted fraction (300 mM imidazole); lane 7: resin after elution. The
anti HA blot confirms the purification of Gaa150-343 by metal (Ni2+ and Co2+) affinity
purification without a His6 tag. A picture of the complete blot is shown in
Appendix C, Figure C.2.
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3.2.3 Gpi823-306-V5-His6 co-immunoprecipitation with Gaa150-343-HA
An HA antibody was used to see if Gpi823-306-V5-His6 would coimmunoprecipitate with Gaa150-343-HA. As controls, we carried out parallel
immunoprecipitation studies with each subunit alone as well (Figure 3.3). As
expected, Gpi823-306-V5-His6 alone did not immunoprecipitate from total cell
lysates with the HA antibody in the absence of Gaa150-343-HA (Figure 3.3, lane 1);
Gaa150-343-HA alone was immunoprecipitated with the HA antibody (Figure 3.3,
lane

2).

When

both

Gpi81-306-V5-His6

and

CPY-Gaa150-343-HA

were

overexpressed together, immunoprecipitation of Gaa150-343-HA led to the coprecipitation of Gpi823-306-V5-His6 (Figure 3.3, lane 3). These results confirm that
Gpi823-306-V5-His6 interacts with Gaa150-343-HA non-covalently. Consequently, it
can also be concluded that the interactions between these two subunits do not
require other GPI-T subunits or transmembrane domains.
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Figure 3.3: Gpi823-306 interacts with Gaa150-343 without its transmembrane
domains or the Gpi16 subunit. (a) A cartoon representation of the interactions
between the soluble domains of Gpi8 and Gaa1. Gpi823-306 coimmunoprecipitated with Gaa150-343 when both Gpi823-306-V5-His6 and Gaa150-343HA were overexpressed together in yeast. (b) Western blot analysis of
immunoprecipitation results using HA antibodies. Top panel: an anti-HA blot
confirming the presence of Gaa150-343-HA in different samples after coimmunoprecipitation. Bottom panel: an anti-V5 blot examining the presence of
Gpi823-306-V5-His6 in different fractions. Blots were generated from the same sets
of samples from two different SDS-PAGE gels that were run in parallel. Lane 1:
Gpi823-306-V5-His6 alone; lane 2: Gaa150-343-HA alone; lane 3: Coimmunoprecipitation of Gpi823-306-V5-His6 with Gaa150-343-HA; lane4: molecular
weight markers. For the image, intervening lanes from the blot were removed for
clarity. These changes are indicated by the presence of a white space separating
the different lanes. A complete gel picture is shown in Appendix C, Figure C.3.
These results indicate that the soluble domains of Gpi823-306 Gaa150-343 interact
with each other in vivo.
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3.2.4 Gpi823-306 co-immunoprecipitates with Gpi1620-551.
The Gpi16 subunit is covalently connected to Gpi8 through a disulfide
bond, and this interaction has been proposed to maintain complex stability.210 In
yeast GPI-T, the residues Cys85 of Gpi8 and Cys202 of Gpi16 form this disulfide
bond.211-212 Even though the exact function of Gpi16 is not known, It has been
proposed that its lumenal domain of Gpi16 has a β-propeller structure that acts
as a funnel that directs the protein substrate into the Gpi8 active site.213-214
To gain further insight into the interactions between Gpi8 and Gpi16, a
Gpi16 soluble domain was constructed as described above using Gateway
cloning technology for overexpression in yeast with galactose induction. Gpi16
has a single C-terminal TM domain (residues 546-568). The Gpi16 construct
(Gpi161-551) was designed by removing this TM domain leaving the native Nterminal ER signal sequence intact. Gpi161-551 was cloned into pAG414-GAL
such that a C-terminal HA tag was added for visualization by Western blot. The
same Gpi8 construct (Gpi81-306-V5-His6), as described above (Section 3.2,
Chapter 3), was used here.
We used an anti-HA antibody for these studies. Gpi81-306-V5-His6 and
Gpi161-551-HA were overexpressed and immunoprecipitated separately and
together, the results are shown in Figure 3.4. Gpi823-306-V5-His6 did not show any
non-specific interactions with either the resin or the antibody (Figure 3.4 (b), lane
4). As expected, Gpi1620-551 alone was successfully immunoprecipitated using an
anti-HA antibody (Figure 3.4 (b),lane 5).
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Figure 3.4: Gpi823-306 specifically co-immunoprecipitates with Gpi1620-551
indicating formation of a heterodimer between these two subunits. (a) A
cartoon representation of the putative interactions between the soluble domains
of Gpi8 and Gpi16 of interest herein. (b) Western blot results from
immunoprecipitation studies conducted with anti-HA antibodies. The top panels
show an anti-HA blot to visualize Gpi1620-551-HA. The bottom panels show results
from an anti-V5 blot to visualize Gpi823-306-V5-His6. Lanes 1-3 contain the lysates
used in these studies, before immunoprecipitation. Lanes 4-6 show the results
after immunoprecipitation. Lanes 1 and 4: Gpi823-306-V5-His6 alone; lanes 2 and 5:
Gpi1620-551-HA alone; lanes 3 and 6: Co-immunoprecipitation of Gpi823-306-V5His6. A complete gel picture is shown in Appendix C, Figure C.4.
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In contrast, when Gpi81-306 was co-expressed with Gpi161-551, these
subunits co-immunoprecipitated as a complex under oxidizing conditions (Figure
3.4, lane 6). Co-immunoprecipitation of Gpi823-306-V5-His6 with Gpi1620-551-HA as
a complex is in contrast to previous findings with human GPI-T that showed that
interactions between these two subunits require their TM domains.215
In wild-type GPI-T, the disulfide bond between Gpi8 and Gpi16 is formed
between C85 (Gpi8) and C202 (Gpi16). To test the importance of these residues
for assembly of the Gpi823-306:Gpi1620-551 complex, each cysteine residue was
mutated to alanine and the co-immunoprecipitation studies described in the
previous paragraph were repeated. These mutations would eliminate the
possibility of disulfide bond formation between Gpi8 and Gpi16. Co-expression
and co-immunoprecipitation studies were conducted with the following protein
combinations: C85A Gpi823-306 with WT-Gpi1620-551, WT-Gpi823-306 with C202A
Gpi1620-551, and C85A Gpi823-306 with C202A-Gpi1620-551 (Figure 3.5). In all cases,
immunoprecipitation of Gpi1620-551-HA using an anti-HA antibody led to coimmunoprecipitation of Gpi823-306-V5-His6 (Figure 3.5). These results demonstrate
that the disulfide bond between Gpi8 and Gaa1 is not essential for the
interactions between the soluble domains of these two subunits.
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Figure 3.5: The disulfide bond between Gpi8 and Gpi16 is not essential for
Gpi823-306 and Gpi1620-551 interactions. Immunoprecipitation studies were
conducted using anti-HA antibody under oxidizing conditions. Each of the lane
contains both Gpi1620-551-HA and Gpi823-306-V5-His6 either with or without the
mutant. Lane1: Co-immunoprecipitation of C85A Gpi823-306-V5-His6 with WT
Gpi1620-551-HA. Lane 2: Co-immunoprecipitation of WT Gpi823-306-V5-His6 with
C202A Gpi1620-551-HA. Lane 3: Co-immunoprecipitation of C85A Gpi823-306-V5His6 with WT Gpi1620-551-HA. The complete picture of this blot is shown in
Appendix C, Figure C.5. Results indicate that Gpi1620-551 interacts with Gpi823-306
even in the absence of the disulfide bond between these two subunits.
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3.2.5 Gaa150-343 assembles into a heterodimeric complex with Gpi1620-551
We also examined the hypothesis that Gpi1620-551 and Gaa150-343 could
form a stable heterodimer in the absence of Gpi8. Gateway cloning technology
was used and a plasmid expressing Gpi1620-551 was constructed with a V5 and a
His6 tag added to its C-terminal. Another plasmid was constructed in which
Gaa150-343 was modified to contain an N-terminal CPY signal sequence and a Cterminal tandem affinity purification (TAP) tag. Co-immunoprecipitation with IgG
resin (targeting the TAP tag) demonstrated that these two subunits also directly
interact with each other, in this case in the absence of Gpi8 (Figure 3.6).
However, additional controls needed to be done to confirm that Gpi1620-551-V5His6 does not have any non-specific affinity for this IgG resin.

3.2.6 The three core subunits of GPI-T co-purify with each other without
their transmembrane regions
The results described above demonstrate that the soluble domains of the
core subunits of GPI-T stably interact with each other in heterodimeric pairs.
Building on these results, we set out to isolate these three soluble domains as a
single complex (Figure 3.7 (a)). Such an accomplishment would open up
innumerable new avenues to further and better characterize GPI-T. It would be of
particular interest to determine if such a complex was catalytically active. We
overexpressed and set out to purify the core complex, containing Gpi81-306-V5His6, Gpi161-551-HA and CPY-Gaa150-343-TAP using the InvSc1 strain of S.
cerevisiae and the plasmids described in previous sections.
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Figure 3.6: Gpi1620-551-V5-His6 co-immunoprecipitates with Gaa150-343–TAP.
(a) A cartoon representation of the putative interaction between Gpi161-551 and
Gaa150-343. (b) Results from immunoprecipitation with IgG resin. The top panel
shows an anti-TAP blot indicating the presence of Gaa150-343-TAP after
precipitation with IgG resin. The bottom panel shows an anti-V5 blot
demonstrating that Gpi1623-551-V5-His6 was isolated with Gaa1. Additional
controls will be run to confirm that this result arose from specific interactions
between the two subunits rather than via non-specific interactions between Gpi16
and the IgG resin. The complete picture of this blot is shown in Appendix C,
Figure C.6.
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Figure 3.7: Tandem affinity purification of Gaa150-343-TAP results in the copurification of Gpi1623-551-HA and Gpi823-306-V5-His6. (a) A cartoon
representation of the putative interactions between Gpi823-306, Gpi1620-551, and
Gaa150-343 of interest herein. (b) Evaluation of the co-purification of Gpi1620-551-HA,
Gpi823-306-V5-His6, and Gaa150-343-TAP. Each fraction along the purification was
tested for the presence of the individual subunits using specific antibodies for
Gpi8 (top), Gpi16 (middle), and Gaa1 (bottom). In all three panels, lane 1:
molecular weight markers; lane 2: cell lysate prior to purification; lane 3: flow
through after lysate was incubated with the calmodulin binding resin; lane 4:
Gaa150-343-TAP after elution from the resin, with its co-purified protein partners;
lane 5: anti-protein A resin after elution. The complete picture of this blot is
shown in Appendix C, Figure C.7.
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This heterotrimeric complex was isolated by TAP tag purification in vitro
using calmodulin binding resin (see materials and methods). The presence of all
three soluble domains was verified by Western blots for each subunits (Figure
3.7). Lanes 2-5 of Figure 3.7 indicates analysis of each fractions along the
purification. When purified using TAP tag, both Gpi823-306-V5-His6 and Gpi1620551-HA

purified along with Gaa150-343-TAP as an intact complex (Figure 3.7, lane

4). These results indicate that the core subunits interact with each other without
their transmembrane regions.

3.2.7 The heterotrimer of the soluble domains of GPI-T has catalytic activity
With a method in hand to purify the three core subunits of GPI-T as a
single complex, we were uniquely positioned to begin to characterize this
complex in vitro for the first time. The foremost goal in our mind was to determine
whether or not this truncated soluble complex retained catalytic activity. Such a
discovery would dramatically improve the ability of researches, including us to
characterize GPI-T.
Our lab has developed a reliable FRET assay that would not only will help
to analyze GPI-T activity as a whole complex, but could also facilitate analysis of
single subunit contributions to GPI-T activity.216 This assay relies on synthetic
peptides modified with a fluorophore (Abz, 2-aminobenzoic acid) and a quencher
(Y*, nitrotyrosine) flanking the ω site amino acid. Our main substrate for this
assay is based on the human campath-1 antigen, or CD52 (Figure 3.8), the
smallest known substrate for GPI-T. After cleavage of its N-terminal ER signal
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Figure 3.8: Transamidation reaction takes place in CD52. (a) Transamidation
reaction. Red color amino acid indicates the fluorophore (Abz or 2-aminobenzoic
acid) and the yellow color amino acid indicates the quencher (3-nitrotyrosine),
which are flanking the ω-site serine shown in pale purple color. The right hand
side contains the two products obtained from the transamidase reaction when
incubated with GPI-T and hydroxylamine (NH2OH). First product is the
hydroxamate that contain the fluorophore and the second product is the part
contains the quencher. (b) Chemical structures of the fluorophore (Abz) and the
quencher (3-nitrotyrosine).
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sequence, CD52 is only 37 amino acids long.217,218,219 We synthesized this
peptide with the addition of the fluorophore (red) and the quencher (yellow) on
either side of the ω-site (pale purple).
When this peptide is incubated with purified GPI-T from yeast with a GPI
anchor mimic such as hydroxylamine,220 the peptide is cleaved at the ω-site
amide, which results in increase Abz fluorescence over time. Previous
experiments carried out to develop this assay were conducted by Dr. Sandamali
Ekanayaka (see Appendix A for more in vitro assay details).216 Dr Ekanayaka
demonstrated that this peptide is a substrate for GPI-T and that GPI-T activity is
dependant on hydroxylamine as a replacement for the full-length GPI anchor
(Figure 3.9 (a).
CD52 was used as the basis for the design and synthesis of two additional
peptides, peptides 2 and 8 (Table 3.1). Several modifications were introduced
into this peptide (shown in bold letters for both peptides, Table 3.1) to avoid any
N-linked glycosylations221 or any oxidations222 (when using the crude lysates) to
make the peptide substrate less complicated. Including these modifications,
peptide 2 was synthesized with an 2-aminobenzoic acid (Abz) group on the Nterminus amino acid and the 3-nitrotyrosine group on the 17th amino acid from
the N-terminus (Table 3.1). Peptide 8 was similar to that of peptide 2 without its
hydrophobic signal sequence.
Using the same protocol developed by Dr. Sandamali Ekanayaka, we
tested the soluble domains of the core subunits for GPI-T activity (Figure 3.9).216
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Table 3.1: Peptide substrates to test GPI-T activity. The peptide substrates
used in this chapter were built from the sequence of CD52. Changes are
highlighted in bold. A 2-aminobenzoic acid (Abz) group was introduced at the Nterminus and a 3-nitrotyrosine (Y*) was inserted in place of Ile17. Peptide 8 is
similar to peptide 2 however it lacks the hydrophobic region of the C-terminal
GPI-T signal sequence.
	
  
Peptide

N–
terminus

N-terminal
sequence

ω
site

Signal sequence

Cterminus

WT-CD52

H2N

GQNDTSETSSP

S

ASSNISGGIFLFFVANAIIHLFCFS

COOH

Peptide 02

Abz

GQKDTSEKSSP

S

ASKNY*SGGIFLFFVAVAIIHLFHFS

COOH

Peptide 08

Abz

GQKDTSEKSSP

S

ASKNY*SGGIFL

COOH

	
  
	
  

	
  
	
  

	
  

99	
  
	
  

(a)

(b)

Full-length GPI-T

NH2OH
dependence

Fluorescence Intensisty (a.u.)

120

100

GPI-T soluble domains
With NH2OH
No NH2OH
No enzyme

80

NH2OH
dependence

60

40

20

0
0

2

4

6

8

10

Time (min)

Figure 3.9: The soluble domains of the core subunits show nucleophile
independent activity. (a) Fluorescence measurements from an in vitro GPI-T
assay conducted with the peptide 2 for the full length GPI-T in the presence (red)
and absence (blue) of 10 mM hydroxylamine. (b) Fluorescence measurements
from an in vitro GPI-T assay conducted with the peptide 2 for the soluble
domains of the core GPI-T subunits in the presence (red) and absence (blue) of
10 mM hydroxylamine. Full length GPI-T shows an NH2OH dependence where
as soluble domains of the core GPI-T subunits show an reduction of NH2OH
dependence.
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Surprisingly, when incubated with peptide 2, a time-dependent increase in
fluorescence was observed but this rate was independent of hydroxylamine; this
result is in contrast to assays with full-length GPI-T, in which measurable activity
was only obtained in the presence of hydroxylamine (Figure 3.9). However, as
observed with wild-type GPI-T, our assay of the solubilized heterotrimer with the
truncated peptide 8 revealed a much slower rate (data not shown). These
preliminary data suggests that the pure soluble hetrotrimer retains some catalytic
activity, however this activity is nucleophile-independent. The most likely
explanation for this activity is that truncation of GPI-T has disrupted the active
site of Gpi8 in a way that is sufficient to convert this enzyme’s normal
transamidation activity into proteolytic activity. However, additional experiments
are need to confirm this scenario.
To better understand these results and to further explore the activity of this
heterotrimeric complex, a carboxyfluorescein (CF) labeled CD52 is being
synthesized. This peptide will be assayed as a substrate for our miniaturized,
soluble GPI-T and any product produced by GPI-T will be characterized by LCMS to confirm that either transamidation or hydrolysis has occurred at the ω site.

3.3 Discussion
We designed and overexpressed soluble domains for each of the three
core subunits of GPI-T to facilitate experiments to examine the structure and
organization of this enzyme. Here we’ve demonstrated that each pair of subunits
can be isolated by immunoprecipitation or by purification, even in the absence of
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the third subunit or any transmembrane domains. We were also able to co-purify
these three soluble domains together in a heterotrimetric complex using only the
TAP tag appended onto the C-terminus of Gaa150-343. Preliminary assays
suggest that this solubilized complex has retained some GPI-T-like catalytic
activity however this activity is nucleophile-independent (unlike full-length, wildtype GPI-T, which requires a nucleophile).
In yeast, the full lengths forms of the core subunits Gpi8, Gpi16 and Gaa1
purify as one complex.18 But the complexity of this complex and the low levels of
purified protein obtained have hindered efforts to further characterize this
enzyme. Here we were able to confirm interactions between the soluble domains
of the core subunits, which will simplify additional analyses. These results
represent just the beginning of a new era for understanding about GPI-T. Using
these interactions, we can now determine the oligomerization states of these
different complexes and, eventually, characterize the different contributions of
each subunit towards GPI-T activity, providing insight into this complicated
enzyme complex that had previously been inaccessible.

3.4 Materials and methods
3.4.1 Buffers and solutions
Minimal medium (4X Sc-ura): 26.8 g Yeast nitrogen base, 6.4 g dropout
mix, 0.4 g each adenine, leucine, tryptophan and histidine in 1L of water and
sterile filtered before use. Minimal medium (4X Sc-trp): 26.8 g Yeast nitrogen
base, 6.4 g dropout mix, 0.4 g each adenine, leucine, uracil and histidine in 1L of
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water and sterile filtered before use. Minimal medium (4X Sc-ura-trp): 26.8 g
Yeast nitrogen base, 6.4 g dropout mix, 0.4 g each adenine, leucine and histidine
in 1L of water and sterile filtered before use. Lysis buffer: 50 mM NaH2PO4, 300
mM NaCl, 10 mM imidazole, pH 7.2. Wash buffer: 50 mM NaH2PO4, 1 M NaCl,
50 mM imidazole, pH 7.2. Imidazole elution buffer: 50 mM NaH2PO4, 300 mM
NaCl, 300 mM imidazole, pH 7.2. Phosphate buffered saline (PBS) buffer: 10 mM
Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 137 mM NaCl, 1 mM CaCl2, 0.5 mM
MgCl2, pH 7.2. Radioimmunoprecipitation assay (RIPA) buffer: 50 mM Tris-HCl,
150

mM

NaCl,

0.25

%

w/v

deoxycholate,

1

%

igepal,

1

mM

(Ethylenediaminetetraacetic acid) EDTA, pH 7.4. Calmodulin binding buffer: 10
mM Tris-HCl, 150 mM NaCl, 1 mM Mg-acetate, 1 mM	
  β-mercaptoethanol (BME),
2 mM CaCl2, pH 8.0. Ethyleneglycoltetraacetic acid (EGTA) elution buffer: 5 mM
Tris-HCl, 10 mM EGTA, 5 mM EDTA, pH 8.0. FRET assay buffer: 50 mM TrisHCl, 0.1 M NaCl, 1 mM MgCl2, 1 mM CaCl2, 1 mM MnCl2, 1 mM dithiothreitol
(DTT), 1 mM phenylmethylsulfonylfluoride (PMSF), and 20 mM reduced
glutathione (GSH), pH 7.4.

3.4.2 Co-purification of the Gpi823-306-V5-His6:Gaa150-343-HA complex using
Ni-NTA affinity purification
Plasmids were constructed using Gateway cloning technology as
described in section 3.2.1, by Dr Yug Varma and Ms Megan Ehrenwerth. Each
gene was amplified using primers with appended AttB sites along with their
native or CPY N-terminal signal sequences. PCR products were transferred into
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the pDONR221 donor vector using standard E. coli transformation protocols and
DH5α competent cells. After sequencing of each construct, genes were
transferred into the appropriate destination vectors using the LR recombination
mix (Invirtogen). Gpi81-306 was inserted into pYES-DEST52 (Invitrogen) and CPYGaa150-343 into pAG414-GAL (Addgene). Both destination plasmids were
transformed individually or together into InvSc1 competent cells using standard
lithium acetate transformation (Invitrogen, pYES-DEST52 Gateway vector
manual).
A 50 mL overnight culture of Gpi81-306-V5-His6:CYP-Gaa150-343-HA or each
single subunit was grown overnight and then transferred into a 1 L cell culture of
the appropriate minimal medium (Sc-ura for Gpi81-306-V5-His6, Sc-trp for CYPGaa150-343-HA

and

Sc-ura-trp

for

Gpi81-306-V5-His6:CYP-Gaa150-343-HA.

Ultimately, cells from a 4 L culture were used for the each experiment. The
cultures were grown in the minimal medium either lacking uracil or tryptophan or
both, depending on the selection markers present in the plasmids used.
Galactose (1%) was added to each large culture (overnight cultures were grown
in 1% glucose) and each culture was grown for 12 hours prior to harvesting of the
cells by centrifugation (3000 rpm for 5 min). Lysis buffer was added to the
harvested cell pellet from a single 4 L cell culture, along with a quarter of a
protease cocktail inhibitor tablet (Roche). An equal volume of glass beads (10
mL) was added to the cell suspension, which was subsequently treated by
vortexing for 30 sec followed by 30 sec on ice for 8 cycles. The cell lysate was
centrifuged at 14,000 rpm for one hour using a JA20 rotor (Beckman Coulter).

	
  
	
  

104	
  
	
  

The cleared supernatant was used for protein purification by Ni-NTA affinity
purification. A 1 mL HisTrap HP column (GE Healthcare) was used for each
purification. The columns were pre-equlibriated by washing each with 10 column
volumes of lysis buffer. Each lysate was passed through a column at a rate of 0.5
mL/min. Then the columns were washed with 5 column volumes lysis buffer
followed by 50 column volumes wash buffer and another 5 column volumes lysis
buffer. Proteins were eluted with 4 mL imidazole elution buffer and the eluent
was concentrated using a 30,000 MW cutoff (Millipore) to a final volume of ~ 150
µL.
Western blots of SDS-PAGE gels were run to confirm the presence of the
protein using the same protocol described in the materials and methods section
of the Chapter 2. Gpi823-306 was visualized using an anti-V5 primary antibody
(Sigma-Aldrich) and Gaa150-343 was visualized using an anti-HA primary antibody
(Sigma-Aldrich).

3.4.3 Co-immunoprecipitation using an HA tag (To evaluate Gpi823-306-V5His6: Gaa150-343-HA and Gpi823-306-V5-His6:Gpi1620-551-HA complexes)
Cell lysate from a 100 mL cell culture was used for immunoprecipitation
assays. Cells were overexpressed as described above, with appropriate
adjustments to the media and volumes. Each cell pellet was resuspended in 1
mL PBS buffer with the addition of a quarter tablet of a Roche protease cocktail
inhibitor. The cells were broken with glass beads as described above (section
3.4.2) and the cell lysate was obtained. An Anti-HA antibody (20 µg from a 1
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mg/mL solution, Sigma Aldrich) was added and the solution was incubated
overnight on a wheel at 4 ºC. A 20 µL sample of protein A agarose resin (SigmaAldrich) was used for the immunoprecipitation studies. The resin was pelleted at
12,000 rpm for 1 min and washed three times with 1 mL RIPA buffer. The resin
was pelleted in between each wash before adding to the lysate/antibody mixture.
The lysate/antibody/resin mixture was incubated with the resin at 4 ºC for 2
hours. The beads were pelleted by centrifugation at 12,000 rpm for 1 min. The
beads were washed four times with 1 mL RIPA buffer each time and one time
with PBS buffer. The beads were pelleted again and then resuspended in 25 µL
2X SDS gel loading dye. This suspension was boiled for 5 min and analyzed
using SDS PAGE gels followed by Western blots as described in Chapter 2,
section 2.4.3. Gpi823-306 was visualized using an anti-V5 primary antibody
(Sigma-Aldrich) and Gaa150-343 and Gpi1620-551 were visualized using an anti-HA
primary antibody (Sigma-Aldrich).

3.4.4 TAP tag purification to isolate heterotrimer
Cells were grown in Sc-ura-trp-leu minimal medium with galactose
induction, essentially as described above. The cells were harvested at 3000 rpm
for 5 min and were lysed using calmodulin binding buffer with the addition of a
quarter tablet of a Roche protease cocktail inhibitor. Cell lysate from a 4 L cell
culture was used for each purification. A 100 µL bed volume of calmodulin
sepharose beads (Sigma-Aldrich), which had been pre-equilibriated by washing
with 20 mL calmodulin binding buffer, was added to a column (Bio-Rad) at 4 ºC.
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The cell lysate was added onto these beads and the slurry was incubated for 2
hours at 4 °C on a rotating wheel. The beads were then washed with 30 mL icecold calmodulin binding buffer at 4 °C. The proteins were eluted with 4 mL EGTA
elution buffer and were concentrated using a 30,000 MW cutoff to a final volume
of ~150 µL. The eluted proteins were analyzed using SDS-PAGE gels followed
by Western blot analysis as described in the materials and methods in chapter 2.
Gpi823-306 was visualized using an anti-V5 primary antibody (Sigma-Aldrich),
Gpi1620-551 was visualized using an anti-HA primary antibody (Sigma-Aldrich),
and Gaa150-343 was visualized using an anti-TAP primary antibody (SigmaAldrich).

3.4.5 FRET assay for the soluble domains
The FRET assay was carried out essentially using the protocol described
in Dr. Sandamali Ekanayaka’s thesis.216 A 20 µL aliquot of a 1 mM peptide
solution (dissolved in DMSO, either peptide 2 or 8) was added to 1.93 mL of
FRET assay buffer. A Cary Eclipse spectrofluorimeter set to the following
parameters: 321 nm excitation wavelength, 417 nm emission wavelength, 10 nm
excitation slit width, 5 nm emission slit width. Each assay was conducted at 30
º

C. The assays were initiated by adding 50 µL of the soluble GPI-T heterotrimer

enzyme and fluorescence emission was monitored over time.

	
  
	
  

107	
  
	
  

3.5 Acknowledgment
I sincerely thank Dr Yug Varma and Ms Megan Ehrenwerth for providing
plasmids and Dr Sandamali Ekanayaka for teaching me the in vitro assay.

	
  
	
  

108	
  
	
  

CHAPTER 4
EFFECT OF GPI-T CORE SUBUNIT OVEREXPRESSION ON
TRANSAMIDASE ACTIVITY IN VIVO
4.1 Introduction
The overexpression of different GPI-T subunits and the upregulation of
certain GPI anchored proteins (e.g. urokinase plasminogen activated receptor;
(uPAR),133 mesothelin, folate receptor alpha, and testisin) in various cancers
make GPI-T a target for chemotherapies.103, 126 In 2008, the Trink group reported
a profile of the expression patterns for the human GPI-T subunits, PIG-K (Gpi8),
GPAA1 (Gaa1), PIG-S (Gpi17), PIG-T (Gpi16), PIG-U (Gab1) (with their
corresponding yeast names in parenthesis) in 19 different cancers.110,187 All five
subunits of GPI-T appear to play a role in different types of cancer
propagation.223 However, the catalytic subunit, Gpi8, is the only subunit that is
frequently downregulated in certain cancers. In this chapter, we describe the use
of an in vivo assay in yeast to assess the contribution of each GPI-T subunit
towards GPI transamidase activity.66 This approach is allowing us to develop
yeast as a cancer model system to understand how changes in GPI-T subunit
expression levels impact the presentation of GPI-anchored proteins on the cell
surface.224-230
We used an in vivo invertase assay that had been previously developed in
our lab,66 to quantify changes in cell surface expression of GPI-anchored
invertase in cell lines that were overexpressing Gpi8, Gpi16, or Gaa1. Different
levels of GPI-T activity were observed based on the subunit that was
overexpressed and the identity of the C-terminal signal sequence appended onto
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invertase. Three signal sequences were examined based on the yeast yapsin 2
protease (Y21), the campath-1 antigen (CA25) and UPAR (UP30). When Gpi8
was overexpressed.

4.2 Results
4.2.1 Invertase assay development
Invertase is commonly used as a reporter assay because it hydrolyzes
sucrose to fructose and glucose and the glucose produced can be measured
using an enzyme coupled colorimetric assay.231
Dr. Rachel Morrisette (an alumna of our lab) previously developed three
Invertase variants that carry different C-terminal GPI-T signal sequences on
them, each with a flag tag for immunoblotting (Figure 4.1 (a)).66 The signal
sequences we used were from the following proteins: S. cerevisiae Yapsin 2
protease (Y21), human campath-1 antigen (CA25) and human urokinase-type
plasminogen-activated receptor (UP30). The plasmids coding these variants
were transformed into an invertase knockout strain (SUC2-).66,209 In wild-type
strains, endogenous invertase is highly secreted as a soluble cytoplasmic protein
in yeast. When invertase is fused with GPI signal sequences and expressed in
the SUC2- strain, GPI anchored invertase is translocated to the outer surface of
the yeast cell membrane (Figure 4.2). The amount of cell surface invertase can
be measured using a standard glucose assay.231 Importantly, this assay is
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(a)

Sc Invertase

INV:
Y21:
CA25:
UP30:

GPI-‐T	
  signal	
  seq.

None
AωGGHNLNPPFFARFITAIFHHI
AωASSNISGGIFLFFVANAIIHLFCFS
AωAAPQPGPAHLSLTITLLMTARLWGGTLLWT

(b)

suc2- strain with
invertase and each GPI-T
constructs

suc2- strain with
invertase construct

Figure 4.1: Invertase variants were constructed with three different GPI-T
signal sequences. (a) Arrangement of invertase variants used herein. Top
panel: cartoon representation of each construct. S. cerevisiae invertase was
modified with a FLAG tag followed by different C-terminal GPI-T signal
sequences. Bottom: the sequences used were from the S. cerevisiae Yapsin 2
protease (Y21), the human campath-1 antigen (CA25) and human UPAR (UP30).
(b) The SUC2- strain was transformed with an invertase construct (right) and a
plasmid coding for overexpression of one GPI-T subunit (left).
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Figure 4.2: GPI anchored invertase localized to the outer cell membrane
through its GPI anchor. (a) Invertase constructed without GPI signal sequence
secreted out in yeast cells. When the cells were washed Invertase can be
removed from the cells. (b) GPI anchored Invertase is localized in the cell
membrane. When washed, Invertase that are not attached with the GPI anchor
washed away leaving GPI anchored Invertase onto the cell membrane.

	
  
	
  

112	
  
	
  

conducted on live cells simply by adding sucrose and then measuring glucose
production.

4.2.2 The effect of endogenous expression of GPI-T on transamidase
activity.
We first recapitulated our previous results using this assay and
endogenous levels of each GPI-T subunit.66,209 The Y21 C-terminal signal
sequence yielded the highest levels of GPI-anchored invertase on the surface of
cells. The activity of the UP30 and CA25 GPI-T signal sequences were
normalized to that of Y21 (Figure 4.3). As we’ve previously reported, the two
human GPI-T signal sequences (UP30 and CA25) are less effective as substrates
for GPI-T. These results suggest species specificity, with yeast GPI-T favoring Cterminal signal sequences from yeast proteins over those from human proteins.
However, this dataset is too small to draw such a conclusion with any certainty.

4.2.3 Effect of Gpi81-441 overexpression on GPI-T activity
The full-length Gpi81-414 gene was amplified by PCR with AttB sites
included within the primers (Appendix C, Table C.1). The product was
incorporated into the destination vector pAG414-GAL-Trp using Gateway cloning
technology. This plasmid appended an HA tag onto the C-terminus of Gpi8 that
was useful for immunoblotting purposes. This plasmid was transformed into the
three SUC2- strains that were carrying the different invertase variants. Gpi8 was
overexpressed by the induction of galactose for 12 hours and the harvested cells
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Figure 4.3: Y21 shows highest GPI-T activity when GPI-T is expressed in
endogenous levels. Bar graph representing the GPI-T activity at endogenous
levels of GPI-T expression. Y21 shows the highest GPI-T activity. UP30 and
CA25 are normalized to that of Y21. Both CA25 and UP30 are weaker substrates
for GPI-T. Raw data are shown in the Appendix C, Figure C.8.
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were assayed immediately for invertase on their cell surface (see materials and
methods).
Overexpression of Gpi81-414 showed some interesting results (Figure 4.4).
The amount of invertase presented on the extracellular plasma membrane was
quantified for each of our three signal sequences under endogenous levels (no
overexpression) and then under conditions where Gpi8 was overexpressed.
Results were normalized against the endogenous levels for each signal
sequence in Figure 4.4 (a) and only against the Y21 levels in Figure 4.4 (b).
Overexpression of Gpi8 had no effect on invertase activity with the constructs
containing either the Y21 or the UP30 GPI-T signal sequence. In contrast,
overexpression of Gpi8 doubled the amount of GPI anchored invertase when the
CA25 GPI-T signal sequence was used. Without Gpi8 overexpression, the CA25
signal sequence was the poorest of the three tested herein. With Gpi8
overexpression, the amount of GPI anchored invertase produced with the CA25
signal sequence rose to levels equivalent to those observed with the UP30 signal
sequence.
We designed our original invertase construct so that, once modified, the
GPI anchored invertase would be the same no matter what signal sequence was
used. Consequently, the amount of invertase presented on the cell surface is
directly correlated to the ability of GPI-T to recognize and process each signal
sequence as a substrate. We had not anticipated the possibility overexpression
of one subunit would show signal sequence dependent changes on GPI-T
activity. Nevertheless, the results in Figure 4.4 clearly show overexpression of
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Figure 4.4: Overexpression of Gpi8 causes an increase in GPI anchoring of
invertase with the CA25 signal sequence specifically. (a) GPI-T anchoring of
invertase normalized to basal level expression levels for each signal sequence.
(b) GPI-T anchoring of invertase normalized specifically to Y21 basal levels. Raw
data are shown in the Appendix C, Figure C.9.
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Gpi8 specifically enhances GPI-T activity when the CA25 signal sequence is
present. These results suggest that Gpi8 recognizes at least part of the Cterminal signal sequence, a scenario that has not previously been considered to
our knowledge.

4.2.4 The effect of Gpi161-610 overexpression on GPI-T activity.
As described above for Gpi8, the full length Gpi16 subunit of GPI-T was
also overexpressed and the impact of this overexpression was assessed by
measuring changes in the amount of GPI anchored invertase present on the cell
surface (Figure 4.5). Compared to cells expressing endogenous levels of the GPIT subunits, the overexpression of Gpi16 diminished the amount of GPI anchored
invertase presented on the cell surface with all three GPI-T signal sequences.
Invertase levels dropped by about 30% when the Y21 signal sequence was used
and by about 60% when either the UP30 or the CA25 signal sequence was used.
The role of Gpi16 in GPI-T is not known although it has been proposed
that this subunit enhances the stability of the complex.232 Here we demonstrate
that excess Gpi16 diminishes the catalytic competence of GPI-T, perhaps
contradicting this stability hypothesis. In Chapter 3 of this dissertation, we showed
that the soluble domain of Gpi16 forms stable dimeric complexes with Gpi8 and
with Gaa1. Presumably excess Gpi16 leads to saturation of these dimeric
complexes (e.g. all Gpi8 is bound to Gpi16) leaving extra Gpi16 to either bind to
Gaa1 and prevent trimer complex formation or to interact with other proteins in
the cell, disrupting normal cell function. The latter scenario is not unprecedented.
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Figure 4.5: Gpi16 overexpression reduces the cell surface expression of
GPI anchored invertase. (a) GPI-T anchoring of invertase normalized to basal
level expression levels for each signal sequence. (b) GPI-T anchoring of
invertase normalized specifically to Y21 basal levels. Raw data are shown in the
Appendix C, Figure C.10.
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In humans, Gpi16 is known to activate several different signal transduction
pathways (see Figure 1.9).

4.2.5 Effect of Gaa11-614 overexpression on GPI-T activity.
Similar to Gpi16, Gaa1 overexpression leads to reduced activity overall In
this case, the impact of individual signal sequences was more varied (Figure 4.6).
A reduction of approximately 45% was observed with the Y21 signal sequence,
65% with the UP30 signal sequence, and 80% with the CA25 signal sequence.
Similar arguments as those proposed for the impact of Gpi16 overexpression can
be made for Gaa1 as well.

4.3 Discussion
Using the invertase assay developed in our lab, we were able to
quantitatively examine the impact of overexpression of the three core GPI-T
subunits on GPI anchoring in vivo. Overexpression of each full-length GPI-T
subunit caused altered levels of GPI anchored invertase that were dependent on
the C-terminal GPI-T signal sequence presented in each construct. The data
presented in Figures 4.4 – 4.6 can be further analyzed in a number of different
ways. Figure 4.7 shows a comparison of these data organized by overexpressed
subunit and Figure 4.8 shows these same data rearranged by signal sequence so
that the impact of each subunit on a specific signal sequence can be easily
observed.
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Figure 4.6: Gaa1 overexpression reduces the cell surface expression of GPI
anchored invertase. (a) GPI-T anchoring of invertase normalized to basal level
expression levels for each signal sequence. (b) GPI-T anchoring of invertase
normalized specifically to Y21 basal levels. Raw data are shown in the Appendix
C, Figure C.11.
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Figure 4.7: Comparison of overall GPI-T activity on single subunit
overexpression. GPI-T activity was measured for basal, Gpi8, Gpi16 and Gaa1
expression. Y21 shows the highest activity on all Invertase variants. UP30 and
CA25 have lower activity compared to Y21. Color coded bars represent each
subunit overexpression.
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The Y21 signal sequence always led to the highest levels of GPI anchored
invertase. Overexpression of Gpi8 and Gpi16 had only nominal effects on GPI
anchoring of invertase with either the Y21 or UP30 signal sequences (compared
to endogenous levels with these signal sequences). In contrast, overexpression
of Gaa1 caused a notable reduction in the amount of GPI anchored invertase
presented on the cell surface.
Like the Y21 signal sequence, overexpression of Gpi8 had little effect on
the amount of GPI anchored invertase present on the cell surface when the UP30
signal sequence was used. In contrast, this signal sequence was sensitive to
overexpression of both Gpi16 and Gaa1, upon which the extent of GPI anchoring
of invertase was diminished.
Finally, the CA25 signal sequence was sensitive to overexpression of all
three GPI-T subunits. Unexpectedly, Gpi8 overexpression doubled the efficacy of
this weak signal sequence; however overexpression of either Gpi16 or Gaa1
reduced anchoring of invertase with this signal sequence.
Overexpression of GPI-T subunits occurs to varying extents in different
types of cancers and between patients. The only subunit that is ever
underexpressed in cancer is Gpi8, the catalytic subunit of GPI-T. Here we show
the first correlations between subunit overexpression and GPI-T activity. It is
possible that subunit overepression can lead to tumorigenesis by altering signal
transduction pathways.
The connection between subunit overexpression and increases in tumor
growth could arise from one of three mechanisms. First, overexpression of a
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single could lead to efficient complex assembly, thereby increasing the overall
activity of GPI-T. Alternatively, subunit overexpression could actually decrease
GPI-T complex assembly by oversaturating dimeric subunit intermediates.
Finally, overexpression could lead to GPI-T subunits that are no in complexes
with their normal protein partners and are therefore free to participate in other
signal transduction pathways (e.g. uPAR in JAKS/STAT pathway).187 Our results
with Gpi16 and Gaa1 clearly favor one of the latter two scenarios because we
see a drop in GPI-T activity. Future efforts will be directed towards examining the
distribution of these overexpressed subunits in vivo to determine whether or not
they are completely free of GPI-T or in complexes with specific GPI-T subunits.

4.4 Materials and methods
4.4.1 Plasmid construction
Each GPI-T plasmid was constructed similarly using Gateway cloning
technology. Each gene was amplified using gene specific primers flanking attB
overhangs. (These primers are listed in Appendix C, Table C.1) Each gene
product was inserted into the pDONR221 vector (Invitrogen) following the
manufacturer’s instructions. The resulting donor vector was used to transfer the
genes into then with the destination vector, pAG414-Trp-GAL (Addgene)
according to Invitrogen’s protocol for an LR reaction. The inserts were
sequenced prior to use. Each was transformed into our SUC2- cell line using
standard LiAc transformation protocols (Invitrogen, pYES-DEST52 Gateway
vector manual).
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4.4.2 In vivo Invertase assay
For each assay, 5 mL cell cultures were used. Cells were grown at 30 ºC
with 1% fructose (for SUC2- cells only with invertase plasmids), or with both 1%
fructose and 1% galactose (for SUC2- cells with both the invertase plasmid and a
plasmid for subunit overexpression) in Sc-Ura or Sc-Ura-Trp media, respectively.
Cultures were grown for 12 hours and then immediately assayed. The OD600 was
measured for each cell culture, and a volume equivalent to 1.0 absorbance unit
was used for each assay. Cells were washed three times with pre-chilled
autoclaved water. To the cells 40 µL of a 1 M NaOAc (pH 4.9) solution was
added and was diluted to 400 µL with autoclaved water. This solution was
incubated at 30 ºC for 30 min. A separate 0.5 M sucrose (in 1 M NaOAc, pH 4.9)
sample was also incubated at 30 ºC prior to use. Next, sucrose (100 µL, 0.5 M
solution) was added to each cell suspension. Time points (50 µL each) were
removed at 1, 2, 3, 4, 5, 8, 11 and 16 min and quenched immediately into 75 µL
of 0.2 M K2HPO4 (pH 10.0) followed by boiling for 3 min. The amount of glucose
present in each time point was measures as previously described. 66,209

4.5 Acknowledgement
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
GPI membrane anchoring of proteins is an important post-translational
modification for eukaryotes. This process and the enzyme that is responsible for
this modification, GPI-T, are poorly understood, particularly relative to their roles
in human cancer. GPI-T contains 5 known subunits: Gpi8, Gpi16, Gaa1, Gab1
and Gpi17. Even after 20 years of study, our understanding of the structure and
function of these subunits remain in its infancy. Therefore, in this dissertation, we
set out to look at the structure, stoichiometry, and contributions of these three
core subunits towards GPI-T activity to better understand this enzyme.
Chapters 2, 3 and Appendix B describe our efforts to structurally
characterize the soluble domains of the three core GPI-T subunits (Gpi823-306,
Gpi1620-551 and Gaa150-343). These three subunits were chosen for study herein
because they are found in all eukarya (Gab1 and Gpi17 are missing in
trypanosomes)74 and they can be isolated as a complex from S. cerevisiae. We
focused our studies on the soluble domains of these subunits in order to simplify
their purification and overexpression.
There is precedent for working with soluble domains in isolation and this
strategy is a common method for characterizing complicated membraneassociated proteins.233,234,235 For example, the toll/interleukin-1 receptor (TIR) is a
membrane protein that resides on the plasma membrane and plays an important
role in inflammation and innate immune response. The crystal structure obtained
from the soluble domain of the TIR10 receptor demonstrated that this receptor
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assembles into a dimer, providing important insight into the function the fulllength, membrane-associated protein.236
We evaluated the soluble domains of these core subunits to understand
how they interact with each other and to reconstitute an active, soluble enzyme
for future studies. This approach is powerful because it reduces the complexity of
GPI-T. In addition, in trypanosomes, the catalytic subunit of GPI-T, Gpi8, is
naturally a soluble protein without a TM domain, offering an interesting precedent
for our approach.81 However, we were mindful of the fact that removing the TM
domains from each subunit could change their behavior in vitro in terms of
oligomerization or activity.
The catalytic subunit, Gpi8, shares weak sequence similarity to caspase1. Caspases are catalytically active as simple homodimers or as homodimers in
complex with specific activating proteins.20 Analogously, Gpi823-306 assembles
into a mixture of homodimer and monomer (Chapter 2). These results suggested
that the transmembrane domain of Gpi8 and/or other subunits are necessary for
complete dimerization. This monomer/dimer Gpi823-306 mixture binds to peptide
substrate but is catalytically inert, leading us to further hypothesize that either
complete dimerization or the presence of one or more additional subunits is
necessary for activity.83 Consistently, our characterization of the trimeric
assembly of Gpi823-306, Gaa150-343 and Gpi1620-551 shows that is has proteolytic
activity, demonstrating that the addition of Gaa1 and/or Gpi16 is sufficient to
activate Gpi8, even in the absence of the native TM domains.
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Also the results obtained from analyses of Gpi823-306 variants with
mutations at N256 offer the first evidence that N23 might be glycosylated, even
though it lies next to the N-terminal signal sequence. Moreover, elimination of Nlinked glycosylation at N256 (via either mutagenesis or the Endo H treatment)
had little effect on the oligomerization state of Gpi8 indicating that N-linked
glycosylation is not critical for Gpi8 dimerization.
With Gpi823-306 as a homodimer, it is logical to hypothesize that the
heterotrimer, containing all three core subunits, would also dimerize (to a dimer
of the heterotrimer, in other words a heterohexamer) (Figure 5.1). In fact, the
preliminary results presented in Appendix B are most consistent with the
conclusion that the Gpi823-306:Gaa150-343 heterodimer is a dimer of dimers (a
heterotrimer) offering additional support for this hypothesis. Thus, work in this
dissertation argues that the three core subunits of GPI-T assemble into a dimer
of trimers.
Data from Chapter 3 show that each pair of subunits assembles into
heterodimeric complexes, offering the first direct evidence that all subunits are in
contact with each other. Furthermore, all three subunits assemble into a
heterotrimer that can be purified by tandem affinity purification. Using a FRET
assay previously developed in our lab,216 we have shown that the soluble
heterotrimer (presumably containing two copies each of Gpi823-306, Gpi1620-551
and Gaa150-343) is catalytically active but, surprisingly, its activity is not dependant
on hydroxylamine. The most likely explanation for this activity is that truncation of
GPI-T has disrupted the active site of Gpi8 in a way that is sufficient to convert
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Figure 5.1: The expected stoichiometry for each of the complexes studied
in this dissertation. The stoichiometry was predicted based on the observations
that Gpi823-306 assembles as a mixture of monomer and homodimer and that
Gpi823-306:Gaa150-343 is likely to exist as a dimer of dimers (heterotetramer).
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this enzyme’s normal transamidation activity into proteolytic activity. In fact, fulllength GPI-T also has proteolytic activity.92
In the future, we would like to further characterize the stoichiometry of
each subunit pair and of the heterotrimer as these experiments will allow us to
map, at least partially, the 3D organization of GPI-T. Our lab will use SEC, native
PAGE and mass spectrometry to examine these soluble subunit mixtures for the
presence of heterotetramer and heterohexamer. We also hope to use covalent
crosslinking coupled to mass spectrometry to map the interfaces between each
subunit. This type of crosslinking approach, coupled to our Rosetta models for
each subunit, will paint a picture of GPI-T’s structure in the absence of any
crystallographic information. As we increase our understanding of the structure of
this enzyme, our ultimate goal will be to obtain a crystal structure of these three
soluble domains in a complex.
It will also be important to use our FRET assay, peptide binding and
crosslinking experiments to evaluate each subunit’s contributions to GPI-T
activity. The FRET assay developed in our lab will be used to determine which
subunits are necessary for a functional GPI-T enzyme. Each subunit pair will be
used to test for GPI-T activity, as we have reported for the heterotrimer in
Chapter 3. The cleaved peptides product(s) will be analyzed using mass
spectrometry to confirm that peptide cleavage occurred at the ω-site. Currently
only the function of Gpi8 is known: this subunit contains the catalytic active site.
And alone, the soluble domain of Gpi8 is inactive.83 To understand which subunit
is responsible for the recognition of the C-terminal signal sequence, our lab will
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use peptides that contain a photoactivated crosslinker (e.g. benzoylphenylalanine
or p-azidophenylalanine) and a tag for co-immunoprecipitation studies. The
peptide will be incubated with the heterotrimer, and irradiated with UV light to
induce crosslinking. The subunits that interact with the peptide can be
immunoprecipitated using the tag on the peptide (e.g. a biotinylated residue) and
analyzed using western blots. The different bands corresponding to each subunit
will be excised and analyzed using mass spectrometry after treating with trypsin.
Chapter 4 and Appendix A of this dissertation describe the use of in vivo
and in vitro assays developed in our lab to functionally characterize GPI-T. As in
Appendix A, a FRET assay was used to examine GPI-T activity in vitro. This
assay is the first reliable in vitro, quantitative assay developed for GPI-T.216
Unfortunately we are still struggling to confirm the formation of the correct
hydroxamate, indicating cleavage and modification at the ω-site residue, due to
complications from the buffer system, such as the presence of digitonin. Once we
confirm the in vitro assay, our lab will use small GPI anchor mimics that were
synthesized by Dr. Franklin John,29 a former member from our lab, as GPI
anchor mimics to test activity. These GPI anchor mimics have structures that are
more similar to the GPI anchor and are likely to be better substrates than
hydroxylamine. Ultimately, our lab will use this assay to examine the impact of
subunit overexpression on GPI-T activity, as an in vitro model for cancer.
Our lab has also developed an in vivo assay using invertase as a reporter
enzyme.66 In chapter 4, this assay was used to assess the impact of
overexpression of each core subunit on GPI-T activity. Our data show two
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unexpected results; first, that activity increases for Gpi8 overexpression
specifically for the signal sequence based on the CD52 protein substrate; and
secondly, GPI-T activity went down upon overexpression of either Gpi16 or Gaa1
independent of the signal sequence tested. These observations have led us to
consider two possible mechanisms for subunit overexpression that could explain
the connections between GPI-T and cancer (Figure 5.2): 1) catalytic subunit
(Gpi8) overexpression is sequence dependent and increases GPI anchoring of
some substrates that will specifically perturb signal transduction pathways; and
2) overexpression of Gpi16 and Gaa1 apparently leads to disruption of the GPI-T
complex, possibly freeing one or more subunits to activate signaling cascades. In
both cases, perturbations of signal transduction pathways would lead to tumor
initiation and propagation. In the future, overexpression of the Gpi17 and Gab1
subunits will also be examined.
This in vivo assay needs to be expanded to include a broader array of
GPI-T signal sequences. Our lab will use more GPI-T signal sequences from
humans (e.g. Glypican 1, Prostatin, Cripto 1 etc.) and yeast (e.g. Yapsin 2,
Phospholipase PLB1 etc.) to better understand how the nature of the substrate
signal sequence and subunit overexpression are connected. Ultimately, it is
important to establish this assay in human cells to more directly examine the
relationship between subunit overexpression and cancer.
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Figure 5.2: Possible mechanism for signal transduction perturbations
based on our results. The overexpression of Gpi8, the catalytic subunit
increases the cell presentation of some GPI anchored proteins that can
perturbate signaling pathways (top). The overexpression of Gpi16 and Gaa1
reduces the cell presentation of GPI anchored proteins by reducing GPI-T
activity. This bottom pathway might be due to the oversaturation of some subunit
interactions leading to excess subunits participating in signal transduction. These
pathways remain poorly understood.
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The work in this dissertation takes an important step forward, providing
new insights into GPI-T and new tools to better characterize this complicated and
important enzyme.

We are only looking at the tip of the iceberg; there is

significant more work to be done.
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APPENDIX A
GPI-T IN VITRO ASSAY PRODUCT CHARACTERIZATION

A.1 Introduction
The complexity of GPI-T has hindered a reliable quantitative assay that
would allow researchers to analyze the kinetics of the protein. Even though there
are many in vivo and in vitro experiments being developed to characterize GPI-T,
the majority of them remain qualitative.81,215,96,55 Placental alkaline phosphatase
(preproPLAP) and its miniature version, preprominiPLAP have been used over
the last few decades in this capacity.55,54,56,237,238 The only in vitro quantitative
assay reported to date is a fluorescence assay that uses a tetrapeptide
containing

the

ω-3

to

ω

residues

of

a

GPI-T

substrate

with

an

aminomethylcoumarin attached to the C-terminus of the ω amino acid.81 Several
limitations were evident in this assay that included long incubation times and the
absence of the C-terminal signal sequences for GPI-T in the synthetic,
tetrapeptide substrate. There is a significant need for better assays with more
comprehensive substrates to completely understand the behavior of GPI-T.
Our lab has been developing a reliable assay base on fluorescence
resonance energy transfer (FRET) that we expect not only to help us analyze
GPI-T, but also to assess the contributions of individual substrates on GPI-T
activity.216 Here we describe the solid-phase synthesis of peptides that are based
on a known substrate for GPI-T (CD52) and have been modified to contain a
fluorophore (2-aminobenzoic acid) and a quencher (nitrotyrosine) flanking the ωsite amino acid (Figure 3.9, Chapter 3).216 CD52 is one of the shortest known
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substrate for GPI-T: this protein is only 37 amino acids long with its C-terminal
signal sequence and once the signal sequence is cleaved the protein is only 12
amino acids in length.217,64,218
When this peptide is incubated with purified GPI-T from yeast with a GPI
anchor mimic like hydroxylamine,220 a time-dependent increase in fluorescence
was observed. These experiments were conducted by Dr. Sandamali Ekanayaka
(data not shown).216

This fluorescence response was consistent with

transamidation by GPI-T. In this appendix, synthesis of two peptide substrates for
this GPI-T assay will be described. These peptides were based on CD52 and on
a yeast substrate for GPI-T called Yapsin 2. Our efforts to confirm that
transamidation had occurred by isolating the hydroxamate peptide product from
this assay will be described. This project is ongoing and is therefore provided as
an appendix.

A.2 Results
A.2.1 Synthesis of peptide substrates using solid phase peptide synthesis
A modified version of our CD52 substrate peptide was synthesized with a
biotin tag added to the side chain of Lys3, the 3rd amino acid from the N-terminus
(peptide 3). Compared to the peptide 2 (Chapter 3) that used to characterize
GPI-T,216 the only modification done onto peptide 3 was the addition of the biotin
tag. This biotin was inserted to facilitate the evaluation of peptide products from
our assay. Additionally, several modifications were introduced into this peptide

	
  
	
  

135	
  
	
  

compared to its native form to avoid N-linked glycosylations (when using crude
yeast lysates)221 or complications that could arise from oxidations222 similar to
peptide 2 (Chapter 3) (Table A.1).
Yapsin 2 is a yeast aspartyl protease, and is a GPI-T substrate with a
validated ω-site.239 Yeast Yapsin 2 also known as Aspartic proteinase MKC7 with
596 aminoacids carrying a molecular weight of 64 kD. It has a N-terminal signal
sequence (residues 1-22) that target the ER localization and a C-terminal signal
sequence (residues 576-596) recognized and modified using GPI-T.75 We have
chosen 21 amino acid long C-terminal signal sequence of Yapsin 2 to create
peptide 11 with additional five amino acid residues towards the N-terminus. We
introduced the Abz, fluorophore to the Lys4, the 4th amino acid from the Nterminus and the 3-nitrotyrosine, quencher onto the 11th amino acid from the Nterminus. We have positioned the fluorophore and the quencher more closely
compared to CD52 to increase the sensitivity of the assay. Also, the N-terminus
of this peptide was acetylated to inhibit any additional modifications that could
take place (Table A.1).
Both peptide substrates were synthesized by solid phase peptide
synthesis using either a Prelude peptide synthesizer or by manual synthesis.
Each substrate was cleaved from the resin, purified by HPLC and characterized
by ESI-MS prior to applications to the study of GPI-T (See materials and
methods).
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Table A.1: The peptides synthesized compared with their native form. Red
colored amino acids are the changes that’s being done compared to the wild type
sequence. Peptide 3 is designed to represent CD52 and peptide 11 was
designed to represent Yapsin 2.

Peptide
CD52
Peptide 3
Yapsin 2

Peptide 11

N-terminal sequence

ω

GPI-T signal sequence

GQNDTSETSSP

S

ASSNISGGIFLFFVANAIIHLFCFS

Abz-GQK(biotin)DTSEKSSP

S

ASKNY*SGGIFLFFVANAIIHLFHFS

STRKE

N

GGHNLNPPFFARFITAIFHHI

(Acetylated)STRK(Abz)E

N

GGHNY*NPPFFARFITAIFHHI
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A.2.2 Purification of GPI-T and in vitro assay for Yapsin2.
Professor Andreas Conzelmann kindly provided us with yeast strain
FBY656. In this strain, the wild-type gpi8 gene has been disrupted with a
kanamycin cassette. Viability of the strain is supported by plasmid YCplac22,
which contains a GST-tagged version of the gpi8 gene. The GST was inserted
into the gene such that it is encoded immediately after the N-terminal ER
localization sequence and before the beginning of the soluble domain of Gpi8
such that the final expressed protein contains the GST sequence followed by
Gpi823-441. GPI-T was purified by glutathione affinity purification according to the
protocol of Fraering et al.216,18 Affinity purification of GST-Gpi81-411 was confirmed
by SDS-PAGE and anti-GST blot, which visualized the presence of Gpi81-411GST (Figure A.1). Insufficient protein was obtained to confirm the co-purification
of Gpi16 and Gaa1 (in contrast to the results of Fraering et. al.).18
Dr. Ekanayaka’s assay development and optimization experiments were
conducted using our synthetic CD52 peptide substrate (peptide 2). Because this
peptide is based on a human substrate for GPI-T, we set out to develop a
substrate based on the yapsin protease, a substrate for S. cerevisiae GPI-T.
216,75

Our expectations were that this peptide would be a stronger substrate for

GPI-T. Therefor, we carried out the in vitro assay with varying peptide
concentrations of peptide 11 (Figure A.2 (a)). Data was normalized to peptide 2,
representing CD52 (Figure A.2 (b)). The red line indicates the background
fluorescence for the assay done without any enzyme. However, even at 5X the
concentration of peptide 2 (the CD52 substrate), activity with our Yapsin 2
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1

2

Figure A.1: Purification of GST-Gpi823-411. An anti-GST blot to confirm the
presence of GST-Gpi823-411. Lane 1: Molecular weight markers, Lane 2: Purified
GST-Gpi823-411, this construct has a calculated molecular weight of 72 kD.
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(a)

(b)
Species-specific substrate and GPI-T

Fluorescence intensity (a.u)

30

10 uM Peptide 2-CD52
10 uM Peptide 11-Yapsin 2
20 uM Peptide 11-Yapsin 2
50 uM Peptide 11-Yapsin 2

25

20

15

10

5

15

50 µM peptide 11

10

Time (min)

20 µM peptide 11

5

10 µM peptide 11

0

10 µM peptide 2

0

Figure A.2: The synthetic Yapsin 2 peptide is not a good substrate for yeast
GPI-T. (a) Initial rates to compare the GPI-T activity on peptide 2 (CD52) and
peptide 11 (Yapsin 2) peptide substrates with different concentrations.(b)The bar
graph shows a comparison of the initial rates obtained from our assay using our
synthetic peptide 2 and peptide 11 peptides. Our peptide11, did not show activity
even at 5X higher concentrations than our typical CD52 assay. The red line
indicates the background fluorescence, the assay conducted without GPI-T (No
enzyme control).
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peptide (peptide 11) was not observed (Figure A.2). (Figure courtesy of Dr.
Sandamali Ekanayaka).216

A.2.3 Analysis of the peptide products from our GPI-T assay
We used peptide 3 (biotynilated version of CD52) (Table A.1) to facilitate
characterization of the peptide products of our GPI-T assay. After an extended
incubation of this peptide with purified GPI-T in the presence of hydroxylamine,
streptavidin purification was carried out to purify all biotin tagged peptides.
Different peptides were separated by high performance liquid chromatography
(HPLC) and then analyzed by ESI-MS. The predicted ω-site of CD52 is Ser12.
Therefore we expected to isolate a peptide containing the 12-N-terminal amino
acids, with the C-terminal serine modified with hydroxylamine to the hydroxamate
by GPI-T. This putative product has a calculated exact mass of 1610 g/mol. The
calculated masses for this peptide as well as other possible biotynilated peptides
are summarized in Table A.2.
However, only masses that roughly matches to the hydroxamates of 4th ,
7th and 8th amino acids from the N-terminus were seen (807, 1124 and 1253 D).
Also we were able to observe two prominent peaks that we initially resembles as
the hydroxyl product of 8th amino acid (1250 D) and it’s hydroxamate product
(1237 D) (Figure A.3). We were surprised to observe multiple cleavage sites and
the predicted ω site was not cleaved. Further analysis of these products
confirmed that the peaks corresponding to 8th amino acid are due to the
presence of digitonin. We used digitonin as a detergent, which will solubilize
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Table A.2: The calculated molecular weights for hydroxamate and hydroxyl
products. Red colored amino acids are the changes that’s being done compared
to the wild type sequence. Molecular weights for both hydroxyl and hydroxamate
products were calculated for assuming cleavage takes place on the 4th, 7th, 8th or
on the 12th amino acid from the N-terminus. All the MW are in g/mol.
Peptide
product

Calculated MW of
the hydroamate
product

Calculated MW
of the hydroxyl
product

Abz-GQK(biotin)DTSEKSSPS

1611

1624

8 mer

Abz-GQK(biotin)DTSEK

1237

1250

7 mer

Abz-GQK(biotin)DTSE

1124

1137

4 mer

Abz-GQK(biotin)D

807

820

12 mer

Sequence
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+ Hydroxylamine

16 kDa
D
162 kDa
D

162 kDa
D

- Hydroxylamine

Figure A.3: Mass spectra of assay product analysis. Two mass spectra are
shown which were acquired from assays conducted in the presence (top) and
absence (bottom) of hydroxylamine.
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GPI-T, the transmembrane protein complex. Digitonin is a glycoside with a
molecular weight of 1229 g/mol. When digitonin is present in a sample, mass
spectrum gives a well-known240,241 pattern with a difference of 162 g/mol between
peaks (Figure A.3). This difference corresponds to the loss of one glucose
molecule.
Next, we introduced a water:chloroform:MgCl2 extraction step into our
assay workup (see materials and methods) to more completely extract the
digitonin from our samples prior to analysis. After extraction, both the aqueous
and organic layers were analyzed in a peptide gel (Figure A.4) and by thin layer
chromatography (Figure A.5) to verify that peptides partitioned into the aqueous
layer with the digitonin in the organic layer. In this case, we used our biotinylated
peptide (see Table A.1) so that partitioning could be visualized by Western blot
after separation in a 20% tris-tricine peptide gel (Figure A.4). As hoped, the
peptide was separated into the aqueous layer. A comparison of lanes 1 and 3 in
Figure A.4 reveals the presence of a shorter peptide in lane 1 that is not present
in lane 4. While it is clear that cleavage of the parent peptide was poor and
incomplete, this smaller peptide may represent the cleavage product from our
assay. In fact, this biotinylated CD52 peptide appears to be a poor substrate for
GPI-T, as judged by the low fluorescence increase observed over time in our
standard assay.
Thin layer chromatography in hexane:ethylacetate with a carbohydrate
specific stain was used to check for the presence of digitonin in the aqueous and
organic layers after extraction. Digitonin and mannitol were tested as controls as
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1 2
W C

3 4 5
W C W

6
C

7

**
*

No nu With nu No E

Anti-biotin blot
Figure A.4: Analysis of extraction step to separate our peptide substrate
from digitonin. A 20% tris-tricine peptide gel was run to analyze the aqueous
(lanes 1, 3, and 5) and organic (lanes 2, 4, and 6) layers from this extraction. The
samples in lanes 1 and 2 are from an assay conducted with hydroxylamine;
Lanes 3 and 4 are from an assay in the absence of hydroxylamine. Lanes 5 and
6 are from a mock assay without GPI-T. Lane 7 contains the biotinylated CD52
peptide as a positive control. *Indicates the band that corresponds to our CD52
substrate. **Indicates a new band that may represent the product peptide from
our assay.	
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1–
2–
3–
4–
5–
6–
7–
8–

Digitonin
No enzyme (C)
No enzyme (W)
With nuc (C)
With nuc (W)
No nuc (C)
No nuc (W)
Mannitol

Digitonin
1

2

3

4

5

6

7 8

Figure A.5: Digitonin can be removed from assay samples by organic
extraction. Peptide samples were separated from digitonin by
water:chloroform:MgCl2 extraction and the organic and aqueous layers were
analyzed by thin layer chromatographic separation. Lanes 2, 4, and 6, represent
the aqueous layers from these extractions; lanes 3, 5, and 7 represent the
corresponding organic layers. Lane 1 shows digitonin without extraction. Lanes 2
and 3 are from a mock assay conducted without enzyme. Lanes 4 and 5 are
from an assay conducted with hydroxylamine. Lanes 6 and 7 are from an assay
conducted in the absence of hydroxylamine.
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both were used in our buffers. Using this method we confirmed that digitonin is
extracted into the chloroform layer, suggesting that peptides in the aqueous layer
are more suitable for analysis by ESI-MS. Efforts are underway to optimize this
method to purify the assay products obtained with peptide 2 (without the biotin
tag), followed by LC-MS to characterize the products.

A.3 Discussion
The importance of GPI-T in human cancer has created an urgent need for
a reliable quantitative assay for this enzyme. A FRET assay was first developed
in our lab using crude microsomes and then with pure GPI-T.216,209 This assay
relies on hydroxylamine as a GPI anchor mimic and reduced activity was seen in
the absence of hydroxylamine, confirming the nucleophilic dependence of this
assay.216
Even using the yeast GPI-T, activity was reduced when a peptide based
on yeast Yapsin 2 was used as a substrate, compared to our human CD52
substrate. However, the Yapsin 2	
   peptide substrate was synthesized with only
three amino acids downstream of the ω-site. It is possible that this truncation
explains the poor substrate behavior of this peptide. A peptide containing a
longer N-terminal sequence is currently being synthesized for testing as a
substrate.
The last step required for the development of our GPI-T assay is to
confirm that transamidation has occurred by demonstrating the formation of a
hydroxamate product. Complications arose due to the presence of digitonin in our
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assay buffer and the biotin tag added on to our CD52 peptide substrate. We have
now developed an extraction protocol to remove the digitonin from our assay.
Efforts to characterize these peptide products are ongoing.
	
  
A.4 Materials and methods
A.4.1 Buffers and solutions
HBTU:

O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium

hexafluorophosphate, DIPEA: N,N-diisopropylethylamine, NMP: N-methyl-2pyrrolidone, cleavage solution: 1.35 mL of Trifluoro Acetic acid (TFA), 50 uL of
Anisole and 95 uL of Thioanisole. Anisaldehyde stain for TLC: 9.2 mL
anisaldehyde, 3.75 mL Acetic acid, 338 mL 95% Ethanol, 12.5 mL concentrated
sulfuric acid.
Peptide gel (20%) preparation:
Gel buffer (3X, pH 8.5), 3 M Tris base, 1 M HCl, and 0.3 % SDS. Separating
layer, 15 mL 39:1 Acrylamide/Bis acrylamide, 10 mL of 3X gel buffer, 2.4 mL of
glycerol, 2.5 mL of water, 100 uL of Ammonium peroxodisulfate (APS), 10 uL of
Tetramethylethylenediamine (TEMED).
Stacking layer, 1 mL of 39:1 Acrylamide/Bis acrylamide, 3 mL of 3X gel buffer, 8
mL of water, 90 uL of APS, 10 uL of TEMED.
2X gel loading dye, 2 mL of Tris HCl pH 6.8, 2 mL of 10% Sodium dodecyl
sulfate (SDS), 4 mL of glycerol, 1.8 mL of water and 5 uL of β-mercaptoethanol
(BME).
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10X Cathode buffer at pH 8.25, 1 M Tris base, 1 M Tricine, and 1% SDS. 10X
Anode buffer, 1 M Tris base, 0.225 M HCl.

A.4.2 Solid phase peptide synthesis
All the peptides were synthesized manually or on a Prelude peptide
synthesizer (Proteins technology). Pre-substituted Fmoc-Ile-Wang resin (for
Yapsin 2 peptides, 100-200 mesh, 0.6 mmol/g) or Fmoc-Ser(tBu)-Wang resin (for
CD52, with a 100-200 mesh, 0.6 mmol/g) were used. All the amino acids were
coupled from 200 mM stock solutions with 400 mM HBTU and 200 mM DIPEA
using NMP as the solvent. The peptides were either doubly coupled as needed.
Manual coupling was performed after testing each amino acid coupling and
deprotection using standard nynhydrin test. Deprotection was achieved with 20%
piperidine in NMP for 20 min to remove the Fmoc group protecting group from
each N-terminal amino acid. The peptides were cleaved from the resin using
peptide cleavage solution, with mixing at room temperature for two hours. Cold
ether was used to precipitate the cleaved peptide. The precipitate was then
lyophilized from water. Each sample was purified by reverse phase HPLC
(Beckman coulter) using a C3 column and ACN: water as the solvent system with
1% TFA. The identity of each peptide confirmed by ESI-MS in collaboration with
the Trimpin Lab).

A.4.3 Purification and assay of GPI-T
The growth, purification and the in vitro assay of GPI-T was conducted
according to the protocols developed by Dr. Sandamali Ekanayaka.216 The
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concentrated proteins were then analyzed using 10% SDS PAGE gel followed by
Western blot. The presence of GST-Gpi8 was visualized by Western blot as
described in the materials and methods of chapter 2.

A.4.4 In vitro assay product analysis for the biotynilated peptide.
After the biotinylated CD52 peptide was incubated with GPI-T under our
standard assay conditions with NH2OH for six hours, the resultant mixture was
loaded onto streptavidin resin (1 mL bed volume) after washing, biotinylated
peptides were eluted with hot.216 The resultant eluent was lyophilized and
analyzed by MAIV, a mass spectroscopic method developed in Dr Trimpin’s lab
and was ran by Dr. Ellen Inutan using 3-Nitrobenzonitrile (3-NBN) as the
matrix.242

A.4.5 Assay product separation using water:chloroform separation
Two milliliter assay samples were used for the extractions. A 3:2:1 ratio of
chloroform:methanol:MgCl2 (4 mM) was added to each assay to become 6 mL
total volumn. Each sample was vortexed for two minutes and then let it to stand
until the layers are settled. The chloroform layer was separated and collected into
a new tube and a second extraction was carried out for the water layer. Both the
water and chloroform layers were separately collected, dried or lyophilized and
frozen until further characterization.
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A.4.6 Peptide gel for product analysis
Samples from the extractions described in the previous section were
analyzed for peptide content using a 20% peptide gel followed by a Western blot
using anti-biotin to detect the biotin tag on our peptide. A 20% separating layer
and a 4% stacking layer were used to prepare the gels (see above). Samples
were loaded onto the gels with 2X gel loading dye (after heat denaturation) and
each gel was ran at 100 V for two hours. The peptide gel was transferred onto
PVDF membrane using similar protocols as in chapter 2 and visualized using
anti-biotin (1 mg/mL, Sigma-Aldrich) followed by secondary anti-mouse
antibodies.

A.4.7 Thin layer chromatographic analysis
TLC was performed with hexane:ethylacetate 50:50 solvent system. The
solvent chamber was saturated first before running the TLC. After elution, the
plate was dried and stained with anisaldehyde to visualize digitonin. To this end,
the TLC plate was sprayed with the stain and then it was heated gently until
spots were visible. Different sugars light up in different colors. A control spot with
pure digitonin was included as a positive control.
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purification and providing with peptides and samples for analysis. Special thanks
goes to Dr Ellen Eutan and Dr Sarah Trimpin assisting us with ESI-MS.

	
  
	
  

151	
  
	
  

APPENDIX B
STRUCTURAL CHARACTERIZATION OF YEAST GPI823-306:GAA150-343
SOLUBLE DOMAINS IN E. COLI

B.1 Introduction
From the five known subunits of GPI-T, Gpi8, Gpi16 and Gaa1 co-purify
as a core-heterotrimer in yeast,18 we consider these three subunits the “core”
components of GPI-T. Even though each subunit is known to be essential for
transamidase activity, the exact contribution of each subunit to activity is
unknown in terms of structure, connectivity, stoichiometry and function.12,19,5, 232
An initial characterization of the soluble domain of the catalytic subunit, Gpi823306,

revealed that it is inactive due either to the absence of one or more of the

other subunits or a requirement for soluble domain II and its TM domain.
Nevertheless, this subunit does bind peptide substrates.83 Therefore, as the next
step, efforts have been initiated to characterize the structural and functional
involvement of the other two core subunits, Gpi16 and Gaa1 (see Chapter 3) .
This appendix describes our efforts towards the structural characterization of
yeast Gpi823-306:Gaa150-343 overexpressed and purified from E. coli.
Gaa1 has a single, large soluble domain with six transmembrane
helices.75 Sequence alignments and the three dimensional structural predictions
by us and others Show an evolutionary connection between Gaa1 and a metaldependant

aminopeptidase.185,186

However,

when

grown

in

E.

coli,

overexpression of Gaa150-343 is toxic.207 To overcome this problem, we
examined the impact of co-expression of Gaa150-343 with GST-Gpi823-306 in E.
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coli. Our hypothesis was that complex formation between these two subunits
would alleviate the toxicity of Gaa1 overexpression. This appendix explains our
efforts towards optimizing growth to maximized the yields of both subunits
(Gpi823-306 and Gaa150-343 and to determine the stoichiometry of this complex.

B.2 Results
B.2.1 Overexpression and purification of Gpi823-306:Gaa150-343
The plasmid pJLM017 (Gaa150-343) was transformed into BL21(DE3)RIL
Codon Plus cells (Stratagene); this plasmid adds a His6 tag onto the N-terminus
of Gaa150-343. Since Gaa150-343 alone is toxic to E. coli, GST-Gpi823-306 (pJLM008)
was co-transformed into this strain in an effort to alleviate toxicity.207 Coexpression was conducted at low temperature. The protein complex was purified
using glutathione affinity purification, which will purify GST-Gpi823-306 along with
Gaa150-343. The purified proteins were analyzed using an anti-GST Western blot,
anti-His blots and Coomassie-stained gels (Figure B.1). Further, these purified
proteins were analyzed using size exclusion chromatography (SEC) and native
PAGE.

B.2.2 Analysis of Gpi823-306:Gaa150-343 complex by SEC.
Native PAGE gels were used to analyze the complex formation between
Gpi823-306 and Gaa150-343; however, they were unsuccessful (data not shown).
Next we injected the purified putative protein complex onto an SEC column.
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(a) 1

2

Anti-GST blot

(b)

1

2

Anti-His blot

(c) 1

2

Coomassie gel

Figure B.1: Glutathione sepharose purification of GST-Gpi823-306 results in
the co-purification of His6-Gaa150-343. GST-Gpi823-306 and His6-Gaa150-343 were
simultaneously overexpressed in BL21(DE3)RIL codon plus cells the GST tag on
GST-Gpi823-306 was used to purify both proteins. (a) Anti-GST Western blot (b)
Anti-His6 blot. (c) Coomassie stained gel. In all three panels, lane 1 molecular
weight markers, Lane 2: purified protein.
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(Figure B.2). Since the amount of protein were not enough to analyze using
native PAGE, the SEC spectra of the complex was overlaid with the SEC
molecular weight marker (Figure B.2 (a)).
Fractions were collected, concentrated and analyzed using SDS-PAGE gels
followed by Western blot visualization using anti-GST and anti-His6 antibodies
SEC exclusion revealed three peaks (Figure B.2 (a)). The first peak
(fractions 4-6) presumably represents aggregates. Western blot analysis
demonstrated that these fractions did not contain either GST-Gpi823-306 or His6Gaa150-343. The second peak (fractions 7-9) was not baseline resolved and
appeared as a shoulder to the first peak. This peak contained both GST-Gpi823306

or His6-Gaa150-343 (Figure B.2. (b)) and eluted with a molecular weight range of

252-164, which is most consistent with the formation of an α2β2 complex,
containing two copies of both GST-Gpi823-306(α) and His6-Gaa150-343 (β). The
third peak eluted with a calculated MW range of 164-70 (fractions 9-10). These
fractions predominantly contain GST-Gpi823-306 and are most consistent with a
homodimer of this subunit. To further confirm the formation of an α2β2
heterotetramer, we set out to optimize the yields of the Gpi823-306:Gaa150-343
expression.
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Figure B.2: SEC analysis of GST-Gpi823-306:His6-Gaa150-343 complex forms a
heterotetramer. GST-Gpi823-306:His6-Gaa150-343 was overexpressed and purified
using glutathione affinity purification. The purified protein was injected into the
SEC column. (a) Spectrum of the complex overlaid with the SEC marker. Blue
color is the spectrum of the complex. Black color id the spectrum of the molecular
weight marker. The eluted fractions were concentrated and analyzed using
western blots of anti-GST and anti-His blots. (b) Top panel: anti-GST western
blot, bottom panel: anti-His western blot. For each lanes, lane 1: molecular
weight marker, lane 2: the injected protein sample, lane 3-10: concentrated
protein fractions collected from the SEC column. If GST-Gpi823-306 is α and His6Gaa150-343 is β, αβ~ 94 kD, α2β~ 153 kD and α2β2~ 188 kD. The protein complex
was observed at a higher molecular weight greater than 150 kD indicates that the
complex is the heterotetramer.

	
  
	
  

156	
  
	
  

B.2.3 Impact of small molecule additives on protein expression and
purification
A number of different small molecules can be added to growth media and
purification buffers to increase protein stability and solubility and to reduce
aggregation of proteins.243 Several additives such as sugars, osmolytes, amino
acids and their derivatives, detergents (non ionic, zwitter ionic and ionic), salts
(mild and strong chaotropes and kosmotropes), alcohols, polyols and polymers
have been used to increase protein stability.243,244,245,246,247 We tested a series of
additives first to increase the solubility of GST-Gpi823-306 and to see the effect of
the small molecules on GST-Gpi823-306 dimerization (Figures B.3 & B.4).
GST-Gpi823-306 was first grown in small scale (25 mL) in the presence of
different small molecules, (erythritol, mannitol, xylitol, trehalose, gly-gly, glycerol
and proline) added to the growth media (see materials and methods). The final
OD600 was measured and each culture was divided into two. One half was
purified in the presence of the same additive and the second half was purified in
the absence. The production of GST-Gpi823-306 was examined using Western
blots with anti-GST antibodies (Figure B.3), native PAGE gels were also used to
test the effect of each additive on protein solubility and protein dimerization
(Figure B.4). However, little effects were observed in terms of protein stability
and solubility for GST-Gpi823-306.
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Figure B.3: The impact of small molecules on the production and stability
of GST-Gpi823-306. Small molecules were used to growth media and purification
buffers in an effort to enhance the overproduction and solubility of GST-Gpi823306. (a) Control growth without any additional small molecules. (b)-(h) Growth
media were supplemented with small molecules, as follows; (b) erythritol, (c)
mannitol, (d) xylitol (e) trehalose (f) gly-gly (g) glycerol and (h) proline. In (a) lane
1: molecular weight markers, and lane 2: affinity purified protein. For panels (b)(h), lane 1: molecular weight markers, lane 2: small molecule was added only to
the growth medium, lane 3: small molecule was added to both the growth
medium and to the lysis buffer used in the purification.
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Figure B.4: Small molecules additives do not enhance dimerization of GSTGpi823-306. GST-Gpi823-306 purified from cultures containing different small
molecule additives was loaded onto a native PAGE gel to analyze the amount of
dimer formed. Lane 1: control protein without any small molecule additive, lanes
2, 4, 6, 8, 10, 12, and 14: Each small molecule was added only to the growth
medium. Lanes 3, 5, 7, 9, 11, 13, and 15: Each small molecule was added to
both the growth medium and the lysis buffer.
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We also tested these small molecules on the overproduction of GSTGpi823-306: His6-Gaa150-343. Cultures were grown separately with each of the small
molecule additives as described above for GST-Gpi823-306. Each cell pellet was
purified with or without the same additive in the purification buffer using
glutathione sepharose affinity purification. The presence of GST-Gpi823-306: His6Gaa150-343 were analyzed using anti-GST and anti-His Western blots, respectively
(Figure B.5).
Gaa150-343 was observed in protein samples, with erythritol added into both
growth medium and to the purification, with trehalose added to the growth
medium and purified even in the presence and absence of trehalose and with
xylitol was added only into the growth medium. However, when trehalose was
added onto the large growth medium (1 L), no protein was overexpressed
indicating this protein complex should grown and purify in small scale cultures.

B.2.4 Switching the tags to increase expression of Gaa150-343
Since the overexpression of Gaa150-343 alone is toxic to the cells and we
couldn’t grow the complex in larger cultures, we assumed by altering the tags it
would help the overexpression of the complex. Therefore we switched tags in
Gpi823-306 to His6 and Gaa150-343 to GST. The individual overexpression and
purification of each protein yield a reasonable quantity of proteins. However,
when both the proteins were expressed in same cell and purified using
glutathione affinity purification, only GST-Gaa150-343 was purified and His6-Gpi823306

was washed during the washing step (Figure B.6).
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Figure B.5: Effect of small molecules on overexpression and purification of
GST-Gpi823-306:His6-Gaa150-343 Both GST-Gpi823-306 and His6-Gaa150-343 was
overexpressed in BL1(DE3)RIL codon plus cells in the presence of small
molecules. Glutathione affinity purified proteins in the presence or absence of
small molecules were analyzed using western blots of anti-GST and anti-His. (a)(h) Top panel: anti-GST blot to visualize GST-Gpi823-306 and bottom panel: antiHis blot to visualized His6-Gaa150-343. (a) Control sample without any sugar. Lane
1: Molecular weight marker, Lane 2: purified protein (b)-(h) Overexpressed and
purified samples with addition of sugar molecules. Lane 1: Molecular weight
maker, Lane 2: Purified protein in the absence of small molecules, Lane 3:
Proteins were purified in the presence of each small molecule.
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Figure B.6: Glutathione affinity purified GST-Gaa150-343 complex didn’t copurify His6-Gpi823-306. Both His6-Gpi823-306 and GST-Gaa150-343 was
overexpressed in BL1(DE3)RIL codon plus cells and purified using glutathione
affinity purification. Top panel: Anti-His blot to indicate the presence of His6Gpi823-306, Bottom panel: Anti-GST blot to confirm the presence of GST-Gaa150343. For both the gels lane 1: molecular weight marker, lane 2: pellet, lane 3:
lysate, lane 4: flow through, lane 5: wash 1, lane 6: wash 5, lane 7: eluted
protein. Lane 5 of the anti-His blot indicate Gpi823-306 has washed and didn’t
participate in forming the complex.

	
  
	
  

162	
  
	
  

These results suggest that His6-Gpi823-306 is not binding to GST-Gaa150-343 may
due to the GST-tag interfering with the Gpi823-306 and Gaa150-343 binding
interface.

B.3 Discussion
Even thought preliminary native PAGE and ESI-IMS-MS results indicate
the presence of the heterotetramer of GST-Gpi823-306: His6-Gaa150-343, we wanted
observe a robust tetramer of this complex. The toxicity of Gaa150-343 when grown
in E.coli has hindered the isolation of the complex in a higher yield. Therefore we
had to carry out optimization of the growth and purification of this protein complex
to increase the yield.
Attempts were carried out to characterize GST-Gpi823-306: His6-Gaa150-343
using SEC, but repetitions were unsuccessful. Therefore to increase the yield of
the protein complex, small molecules were added to the growth medium. Even
thought the addition of small molecules onto the growth medium, didn’t enhance
the solubility and stability of the Gpi823-306-GST, in GST-Gpi823-306: His6-Gaa150343

a higher yield of the complex was obtained with erythritol, trehalose and xylitol

in small growth cultures. When small molecules were used in larger cultures
protein complex was not overexpressed leading us to think that may be amount
of air and the cell crowding may effect on the protein’s expression. Therefore,
growth should carryout in small scale, to obtain a higher yield of the protein and
re-analyze for the heterotetramer should done using native PAGE and SEC.
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B.4 Materials and methods
B.4.1 Overexpression and purification of GST-Gpi823-306: His6-Gaa150-343
Plasmids were constructed by Dr Y. Varma and Dr R. Morissette.207,209
Overexpression and purifications were carried according to Dr. Varma’s
protocols.207 The presence of proteins was confirmed by SDS-PAGE gels
followed by Western blots. Anti-GST Western blots done similar to Chapter 2,
materials and methods. Anti-His western blots were carried out with a 1 µg/mL
concentrations of anti-His primary antibody from mouse (AnaSpec) followed by
the

secondary

anti-mouse

antibodies

(Sigma-Aldrich)

with

a

working

concentration of 1 µg/mL.

B.4.2 Use of small molecules in overexpression and purification of GSTGpi823-306 and GST-Gpi823-306: His6-Gaa150-343 complex
Overnight pre-cultures were grown without any small molecules. A volume
of 1 mL pre-culture was added to a 25 mL culture with appropriate antibiotics and
1% glucose, along with small molecules to obtain the following final
concentrations. erythritol: 0.5 M, mannitol: 0.5 M, xylitol: 1 M, trehalose: 0.75 M,
gly-gly: 0.1 M and glycerol: 5%, proline, 0.5 M.243 Samples were grown at 19 oC
until it reaches the OD600 to ~0.5. Once the desired OD600 was obtained, a final
concentration of 1 mM IPTG was added and was induced for another two hours.
The final OD600 was measured prior to the purification. The cell pellet was
dissolved to obtain a similar concentration of cells and was purified following the
same protocols for GST purifications as described in Dr Varma’s thesis.207
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The purified cells were analyzed using SDS-PAGE gels and native PAGE
gels where appropriate followed by anti-GST and anti His Western blots as
described in materials and methods of Chapter 2.

B.4.3 Switching tags to obtain His6-Gpi823-306: GST-Gaa150-343 complex
Plasmids pJLM008 (GST-Gpi823-306) and pJLM017 (His6-Gaa150-343) was
used to obtain the His6-Gpi823-306 and GST-Gaa150-343 plasmids. The restriction
enzyme cleavage was done to get Gpi823-306 and Gaa150-343 gene products and
was inserted into pCDF-1B and to pGEX-4T3 plasmids respectively to switch the
tags.
Glutathione sepharose affinity purification was used to purify the complex.
The protocols for overexpression and purification of these proteins are similar to
previous.
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APPENDIX C
EXPANDED FIGURES AND TABLES
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Figure C.1: Extended gel pictures with respect to Figure 2.1.
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Figure C.2: Extended gel pictures with respect to Figure 2.2.
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Figure C.3: Extended gel pictures with respect to Figure 2.5.
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Figure C.4: Extended gel pictures with respect to Figure 2.9.
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Figure C.5: Extended gel pictures with respect to Figure 3.2.
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Figure C.6: Extended gel pictures with respect to Figure 3.3.
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Figure C.7: Extended gel pictures with respect to Figure 3.4.
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Figure C.8: Extended gel pictures with respect to Figure 3.5.
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Figure C.9: Extended gel pictures with respect to Figure 3.6.
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Figure C.10: Extended gel pictures with respect to Figure 3.7.
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Figure C.11: Raw data, for Figure 4.3.
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Figure C.12: Raw data for Figure 4.4.
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Figure C.13: Raw data for Figure 4.5.
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Figure C.14: Raw data for Figure 4.6.
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ABSTRACT

BIOCHEMICAL AND STRUCTURAL CHARACTERIZATION OF THE CORE
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Glycosylphosphatidylinositol transamidase (GPI-T) is a complicated,
membrane-bound, multi-subunit enzyme that catalyzes an essential posttranslational modification. This enzyme attaches GPI anchors to the C-termini of
various proteins that contain a proper GPI-T signal sequence. Gpi8, Gaa1,
Gpi16, Gpi17 and Gab1 are the five known subunits that may encompass the
fungal GPI-T; Gpi8 is the catalytic subunit, but the functions of the other subunits
remain essentially unknown. In humans, different GPI-T subunits are upregulated
in different cancers, making GPI-T a target for cancer research. However, in spite
of the importance of this enzyme, little is known about how it assembles into an
active enzyme complex, the stoichiometry of this complex, or the roles of the
different components. Here we use soluble domains of the three core subunits
(Gpi8, Gpi16 and Gaa1) to investigate the stoichiometry of the enzyme as well as
to study the functions of each subunit in vitro. Additionally, overexpression of the
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full-length core subunits was used to study the enzyme’s behavior on
transamidation in vivo.
Due to the complex nature of this protein and the fact that it is membrane
associated, we set out to simply this enzyme into a more tractable system. In
chapters 2 and 3 of this thesis, we focused on the soluble domains of the core
subunits, Gpi81-306, Gaa150-343 and Gpi161-551. These soluble domains were
overexpressed and their interactions and stoichiometry were characterized. Gpi8,
the catalytic subunit, has weak sequence similarity to caspase-1 and assembles
into a homodimer. Also, N-linked glycosylation of one asparagine in this subunit
is not essential for dimerization. Co-immunoprecipitation of the soluble domains
of

Gpi81-306:Gaa150-343,

Gpi81-306:Gpi161-551

and

Gpi161-551:Gaa150-343

demonstrated that these subunits interact with each other at least in
heterodimeric complexes. Initial characterization of the Gpi823-306:Gaa150-343
complex is consistent with the formation of an α β heterotetramer. Also, these
2

2

three subunits Gpi81-306:Gaa150-343:Gpi161-551 can be co-purified as an intact
complex. Preliminary results show that this core heterotrimer has nucleophileindependent activity. Our results will help to elucidate the function and resolve
the complexity of GPI-T. Efforts are underway to determine the stoichiometry of
each subunit and the contribution of each subunit towards transamidase activity.
To better understand how changes in expression affect GPI-T activity, and
as a model for this enzyme in cancer, we have developed an in vivo strategy to
monitor and quantify the effect of subunit overexpression on cell surface
presentation of GPI-anchored proteins in Saccharomyces cerevisiae. Here we
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used Invertase as a reporter enzyme. Three GPI-T signal sequences were
appended to the C-terminus of invertase and the amount of cell surfaced, GPI
anchored invertase was measured. Overexpression of Gpi8, the catalytic subunit
had little effect on GPI anchoring of invertase with two of these three signal
sequences; however, the amount of cell surface invertase was nearly doubled
when

the

weakest

signal

sequence

was

used.

Compared

to

Gpi8,

overexpression of either Gpi16 or Gaa1 downregulated GPI-T activity with all
three signal sequences. To our knowledge, these results represent the first direct
examination of the impact of subunit overexpression directly on GPI-T activity.
Our results suggest that overexpression of a single GPI-T subunit either disrupts
assembly of active GPI-T or frees these subunits to participate different cellular
functions.
The results presented in this dissertation represent the beginning of a new
era aimed at understanding GPI-T and provide new tools and approaches to
achieve this important goal.	
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